BR122019026127B1 - RECOMBINANT HOST CELL AND CELL CULTURE - Google Patents

Abstract

the disclosure refers to recombinant host cells that include effective strain modifications to improve the titer, yield and/or productivity of fatty acid derivatives. The disclosure further relates to cell cultures that include recombinant host cells for the fermentative production of fatty acid derivatives and compositions thereof.

Description

CROSS REFERENCE TO RELATED ORDERS

[001] This application claims the benefit of Interim Application in U.S. 61/619,324, filed April 2, 2012, which is incorporated in its entirety by reference.

SEQUENCE LISTING

[002] The present application contains the Sequence Listing which was sent in ASCII format via EFS-Web and is incorporated herein in its entirety by way of reference. Said ASCII copy, created on April 2, 2013, is named as LS00042PCT_SL.txt and is 143,098 bytes in size.

FIELD

[003] The application relates to recombinant host cells including strain modifications effective in improving titration, yield and/or productivity of fatty acid derivatives. The disclosure further relates to cell cultures including recombinant host cells for the fermentative production of fatty acid derivatives and compositions thereof.

BACKGROUND

[004] Fatty acid derivatives including fatty aldehydes, fatty alcohols, hydrocarbons (alkanes and olefins), fatty esters (eg waxes, fatty acid esters or fatty esters) and ketones constitute important categories of industrial chemicals and fuels. These molecules and their derivatives have numerous applications including, but not limited to, use as surfactants, lubricants, plasticizers, solvents, emulsifiers, emollients, thickeners, flavors, fragrances and fuels. Crude oil is currently a major source of raw materials to produce petrochemicals and fuels. The two main classes of crude oil-derived materials are short-chain (eg, ethylene and propylene) and aromatic (eg, benzene and xylene isomers) olefins. These crudes are derived from longer chain hydrocarbons in crude oil by cracking it at considerable cost using various methods such as catalytic cracking, steam cracking or catalytic reforming. These crude materials can be used to produce petrochemical substances such as monomers, solvents, detergents and adhesives that cannot otherwise be directly refined from crude oil. Petrochemical substances, in turn, can be used to produce special chemical substances, such as plastics, resins, fibers, elastomers, pharmaceutical substances, lubricants, gels and the like. Particular specialty chemicals that can be produced from petrochemical raw materials include, but are not limited to, fatty acids, hydrocarbons, fatty aldehydes, fatty alcohols, esters, and ketones.

[005] Hydrocarbons, for example, have several commercial uses. Therefore, shorter chain alkanes and alkenes are used in transport fuels. Longer chain alkenes are used in plastics, lubricants, and synthetic lubricants. Additionally, alkenes are used as a raw material to produce alcohols, esters, plasticizers, surfactants, tertiary amines, enhanced oil recovery agents, fatty acids, thiols, alkenylsuccinic anhydrides, epoxides, chlorinated alkanes, chlorinated alkenes, waxes, additives of fuel and drag flow reducers. Similarly, esters have many commercial uses. For example, biodiesel, an alternative fuel, is made from esters (eg fatty acid methyl ester, fatty acid ethyl esters, etc.). Some low molecular weight esters are volatile and have a pleasant smell, which makes them useful as fragrances or flavoring agents. Additionally, esters are used as solvents for lacquers, paints and varnishes. Furthermore, some naturally occurring substances such as waxes, fats and oils are also made from esters. Esters are additionally used as softening agents in resins and plastics, plasticizers, flame retardants and additives in gasoline and oil. Additionally, esters can be used in the manufacture of polymers, films, textiles, dyes and pharmaceutical substances.

[006] Aldehydes are used to produce a wide variety of specialty chemicals. For example, aldehydes are used to make polymers, resins (e.g. Bakelite), dyes, flavors, plasticizers, perfumes, pharmaceuticals and other chemicals, some of which can be used as solvents, preservatives or disinfectants. Additionally, certain natural and synthetic compounds, such as vitamins and compounds used as hormones, are aldehydes. In addition, many sugars contain aldehyde groups. Fatty aldehydes can be converted to fatty alcohols through chemical or enzymatic reduction. Similarly, fatty alcohols have many commercial uses as well. Shorter chain fatty alcohols are used in the cosmetics and food industries as emulsifiers, emollients and thickeners. Due to their amphiphilic nature, fatty alcohols behave as non-ionic surfactants, which are useful in personal and household care products such as, for example, detergents. Additionally, fatty alcohols are used in pharmaceutical waxes, gums, resins, ointments and lotions, lubricating oil additives, textile finishing and antistatic agents, plasticizers, cosmetics, industrial solvents and grease solvents. Fatty alcohols such as aliphatic alcohols include a chain of 8 to 22 carbon atoms. Fatty alcohols typically have an even number of carbon atoms and a single alcohol (OH) group attached to the terminating carbon. Some are unsaturated and some are branched. They are widely used in industrial chemistry. Most fatty alcohols in nature are found as waxes which are esters with fatty acids and fatty alcohols. They are produced by bacteria, plants and animals. Currently, fatty alcohols are produced through the catalytic hydrogenation of fatty acids produced from natural sources such as coconut oil, palm oil, palm kernel oil, tallow and lard, or by chemical hydration of alpha- olefins produced from petrochemical raw materials. Fatty alcohols derived from natural sources have varying chain lengths. The chain length of fatty alcohols is important and specific for particular applications. Dehydration of fatty alcohols to alpha-olefins can also be achieved by chemical catalysis.

[007] Due to the inherent challenges presented by the exploration, extraction, transport and refining of petroleum for use in chemicals and fuels, there is a need in the art for an alternative source that can be produced economically and efficiently for use in chemical and fuels. Furthermore, the burning of petroleum-based fuels has become a serious threat to the environment, especially in light of the permanent growth of the population that inhabits the planet. Thus, there is a need for a petroleum substitute that does not cause the kind of environmental damage created by the exploration, extraction, transport and refining of petroleum.

[008] One option for producing renewable petroleum is to engineer the host cells to produce renewable petroleum products. Biologically derived fuels and chemical substances offer advantages compared to petroleum-based fuels. Biologically derived chemicals, such as hydrocarbons (eg, alkanes, alkenes, or alkynes), fatty alcohols, esters, fatty acids, fatty aldehydes, and ketones are directly converted from biomass into the desired chemical. However, in order to use fatty acid derivatives biologically derived from fermentable sugars or biomass to be commercially viable as a source for the production of chemicals and renewable fuels, the process needs to be improved for efficient conversion and recovery of the product. The development of biologically derived fuels and chemicals has been a focus of research and development in recent years. Still, there remains considerable need for improvements in relevant processes and products in order for biologically derived fuels and chemicals to become a commercially viable option. Areas in need of improvement include the energy efficiency of the production process and the yield of the final product. The present revelation addresses that need.

SUMMARY

[009] One aspect of the disclosure provides a recombinant host cell that has a genetically modified polynucleotide sequence, wherein the polynucleotide sequence encodes one or more polypeptides that have a specific enzymatic activity. The polynucleotide sequence is exogenous or endogenous to the host cell. Accordingly, the disclosure provides a recombinant host cell that has a genetically modified polynucleotide sequence that encodes one or more polypeptides, the polypeptides having an activity selected from the group including, but not limited to, 3-hydroxydecanoyl activity. -[acp] dehydratase (EC 4.2.1.60); β-ketoacyl-ACP synthase I activity (E.C. 2.3.1.41); β-ketoacyl-ACP synthase II activity (E.C. 2.3.1.179); [acp] S-malonyltransferase {malonyl-CoA-ACP transacylase} activity (E.C. 2.3.1.39); 3-oxoacyl-{β-ketoacyl}-ACP reductase activity (E.C. 1.1.1.100); β-ketoacyl-ACP synthase III activity (E.C.2.3.1.180); enoyl-ACP reductase (NADH) activity (E.C. 1.3.1.9); enoyl-ACP reductase (NADPH) activity (E.C. 1.3.1.10); 3-hydroxy-acyl-[acp] dehydratase activity (E.C. 4.2.1.59); and trans-2, cis-3-decenoyl-ACP isomerase (EC 5.3.3.14) activity, wherein the recombinant host cell produces a fatty acid derivative composition at a higher titer, yield or productivity than a host cell of the corresponding wild type when grown in a medium containing a carbon source under conditions effective to express the polynucleotide. In a related aspect, the recombinant host cell produces the fatty acid derivative composition at a higher titer, yield and/or productivity when the polypeptide is expressed in combination with at least one other polypeptide of enzymatic activity. In another aspect, the recombinant host cell produces the fatty acid derivative composition at a higher titer, yield or productivity when the polypeptide is expressed in combination with at least five other polypeptides of enzymatic activity. In yet another aspect, the recombinant host cell produces the fatty acid derivative composition at a higher titer, yield or productivity when expressed in combination with at least two or three or four or five or six or more polypeptides of enzyme activity. In another related aspect, the recombinant host cell includes one or more genetically modified polynucleotide sequences that additionally encode a polypeptide that is an acyl carrier protein (ACP). ACP can be expressed in combination with one or more of the polypeptides encoding any of the enzymatic activities, whereby ACP further enhances the titer, yield and/or productivity of the recombinant host cell when cultured under appropriate conditions. In yet another related aspect, a genetically modified polynucleotide sequence additionally encodes a polypeptide that has an accABCD activity (E.C. 6.4.1.2). accABCD can be expressed in combination with one or more of the polypeptides encoding any of the enzymatic activities, with accABCD further increasing the titer, yield and/or productivity of the recombinant host cell when cultured under appropriate conditions.

[0010] Another aspect of the disclosure provides a recombinant host cell that has a genetically modified polynucleotide sequence that encodes one or more polypeptides, the polypeptides having an enzymatic activity that includes, but is not limited to, trans-2, cis- 3-decenoyl-ACP isomerase (fabA or fabM); β-ketoacyl-ACP synthase I (fabB); malonyl-CoA-ACP transacylase (fabD); β-ketoacyl-ACP synthase I (fabF or fabB); β-ketoacyl-ACP reductase (fabG); β-ketoacyl-ACP synthase III (fabH); enoyl-ACP reductase (fabI or fabL or fabV or fabK); and 3-hydroxy-acyl-[acp] dehydratase (fabA or fabZ); trans-2-enoyl-ACP reductase II (fabK). In a related aspect, the polypeptide is selected from fabA, fabB, fabD, fabF, fabG, fabH, fabI, fabL, fabV, fabZ, fabM, and fabK and or combinations thereof. In yet another related aspect, the polypeptide is selected from Salmonella typhimurium FabA (NP_460041); Escherichia coli FabB (NP_416826); Salmonella typhimurium FabD (NP_460164); Salmonella typhimurium FabG (NP_460165); Salmonella typhimurium FabH (NP_460163); Salmonella typhimurium FabZ (NP_459232); Streptococcus mutans FabM (AAN59379); Streptococcus pneumoniae FabK (AAF98273); Vibrio cholera FabV (YP_001217283); Clostridium acetobutylicum FabF (NP_350156); FabI from Bacillus subtilis subsp. subtle str. 168 (NP_389054); FabL from Bacillus subtilis subsp. subtle str. 168 (NP_388745); FabI to Acinetobacter sp. ADP1 (YP_047630); Marinobacter aquaeoli VT8 FabI (YP_958813); Rhodococcus opacus B4 FabI (YP_002784194); FabH from Acinetobacter sp. ADP1 (YP_046731); Marinobacter aquaeoli VT8 FabH (YP_958649); and Rhodococcus opacus B4 FabH (YP_00278448) or combinations thereof.

[0011] The disclosure further contemplates a recombinant host cell that has a genetically modified polynucleotide sequence that encodes an ACP polypeptide, wherein the recombinant host cell produces a fatty acid derivative composition at a titer, yield or productivity greater than a corresponding wild-type host cell when cultured in a medium containing a carbon source under conditions effective to express the ACP polypeptide. In a related aspect, the genetically modified polynucleotide sequence additionally encodes a polypeptide that has a phosphopantetheinyl transferase activity (E.C. 2.7.8.7). In the present document, the genetically modified polynucleotide sequence includes an sfp gene encoding a phosphopantetheinyl transferase (E.C. 2.7.8.7). In a related aspect, a genetically modified polynucleotide sequence additionally encodes a polypeptide that has an accABCD activity (E.C. 6.4.1.2). ACP can be expressed in combination with accABCD and/or with a phosphopantetheinyl transferase, with the combination of any of the expressed polypeptides leading to further increases in titer, yield and/or recombinant host cell productivity when cultured under appropriate conditions. In another related aspect, ACP is derived from the same organism as a terminal pathway enzyme expressed in the recombinant host cell, with the terminating enzyme cleaving any acyl-ACP species that is part of the fatty acid biosynthetic pathway. The ACP is exogenous or endogenous to the host cell.

[0012] The disclosure further encompasses a recombinant host cell that includes a genetically modified polynucleotide sequence including a transposon, wherein the insertion of the transposon into a yijP gene affects a second gene flanking the yij gene, the second gene encoding for a polynucleotide that is up- or down-regulated and wherein the up- or down-regulated polynucleotide encodes a polypeptide that affects the production of a fatty acid derivative composition when the host cell is cultured in a medium containing a carbon source under effective conditions to express the polypeptide. The yijP gene can be flanked by genes on either side. In a related aspect, insertion of the transposon into the yijP gene results in inactivation of the yijP gene or a polynucleotide thereof, which affects one or more of the genes that flank the yijP gene, with the flanking gene or genes encoding a polypeptide that affects the production of a fatty acid derivative composition when the host cell is cultured in a medium containing a carbon source under conditions effective to express the polypeptide. In a related aspect, the flanking gene includes polynucleotides that include, but are not limited to, ppc, yijO, frwD, pflC, pflD, or argE.

[0013] Another aspect of the disclosure provides a recombinant host cell including a genetically modified polynucleotide sequence that encodes a phosphoenolpyruvate carboxylase (ppc) polypeptide, wherein the recombinant host cell produces a fatty acid derivative composition at a titer, yield or higher productivity than a corresponding wild-type host cell when cultured in a medium containing a carbon source under conditions effective to express the ppc polypeptide.

[0014] Yet another aspect of the disclosure provides a cell culture that includes any of the recombinant host cells set forth herein (supra). The recombinant host cell is cultured in a medium such that the recombinant host cell produces fatty acid-derived compositions in accordance with the genetic engineering methods presented herein (supra). In a related aspect, fatty acid-derived compositions produced by the recombinant host cells of the present disclosure include, but are not limited to, fatty acids, fatty esters, fatty alcohols, fatty aldehydes, alkanes, terminal olefins, internal olefins, and ketones. In another related aspect, the fatty acid derivative is a C6, C8, C10, C12, C13, C14, C15, C16, C17 or C18 fatty acid derivative. In yet another related aspect, the fatty acid derivative is a C10:1, C12:1, C14:1, C16:1 or C18:1 unsaturated fatty acid derivative. In a further related aspect, the fatty acid derivative composition comprises one or more of C8, C10, C12, C14, C16 and C18 fatty acid derivatives. Compositions derived from fatty acids produced by cell cultures containing the recombinant host cells of the present disclosure include fatty acids, fatty aldehydes, fatty alcohols, fatty esters, alkanes, terminal olefins, internal olefins and ketones. The disclosure further encompasses fatty acid-derived compositions that include fatty acid derivatives that have a 7-position double bond on the carbon chain between C7 and C8 from the reduced end of the fatty alcohol; fatty acid-derived compositions that include unsaturated fatty acid derivatives; fatty acid-derived compositions that include saturated fatty acid derivatives; and fatty acid-derived compositions that include branched-chain fatty acid derivatives.

[0015] The disclosure further contemplates a cell culture that contains any of the recombinant host cells set forth herein, wherein the recombinant host cells have a titer that is at least about 5% higher than the titer of the type host cell. wild type when grown under the same conditions as the recombinant host cells. In the present document, recombinant host cells have a titer of from about 1 g/l to about 250 g/l, and more specifically, from about 90 g/l to about 120 g/l. In a related aspect, the recombinant host cells have a yield that is at least about 10% to about 40%. In one aspect, the recombinant host cells have a yield of about 25%. Further encompassed herein is a cell culture that contains any of the recombinant host cells set forth herein, wherein the cell culture productivity ranges from about 0.7 mg/l/h to about 3 g/l/h or larger.

[0016] Another aspect of the disclosure provides methods for producing a recombinant host cell including genetically engineering the recombinant host cell such that the cell expresses a polypeptide sequence that is encoded by one or more polynucleotide sequences under specific culture conditions, wherein the polynucleotide sequence encodes one or more polypeptides that have a specific enzymatic activity.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The present disclosure is better understood when read together with the accompanying Figures, which serve to illustrate preferred embodiments. It is understood, however, that the disclosure is not limited to the specific modalities revealed in the Figures.

[0018] Figure 1 presents an exemplary biosynthetic pathway for use in the production of acyl CoA as a precursor for fatty acid derivatives in a recombinant microorganism. The cycle is initiated by the condensation of malonyl-ACP and acetyl-CoA.

[0019] Figure 2 shows an exemplary fatty acid biosynthetic cycle, in which malonyl-ACP is produced by the transacylation of malonyl-CoA to malonyl-ACP (catalyzed by malonyl-CoA:ACP transacylase (fabD)); and then β-ketoacyl-ACP synthase III (fabH) initiates the condensation of malonyl-ACP with acetyl-CoA. Elongation cycles begin with the condensation of malonyl-ACP and an acyl-ACP catalyzed by β-ketoacyl-ACP synthase I (fabB) and β-ketoacyl-ACP synthase II (fabF) to produce a β-keto-acyl-ACP synthase. ACP, then β-keto-acyl-ACP is reduced by β-ketoacyl-ACP reductase (fabG) to produce a β-hydroxy-acyl-ACP, which is dehydrated to a trans-2-enoyl-acyl-ACP by β -hydroxyacyl-ACP dehydratase (fabA or fabZ). FabA can also isomerize trans-enoyl-acyl-ACP to cis-3-enoyl-acyl-ACP, which can use fabI and can be used by fabB (typically up to a maximum aliphatic chain length of C16) to produce β -keto-acyl-ACP. The final step in each cycle is catalyzed by enoyl-ACP reductase (fabI) which converts trans-2-enoyl-acyl-ACP to acyl-ACP. In the methods described herein, termination of fatty acid synthesis occurs by removal of thioesterase from the acyl group from acyl-ACP to release free fatty acids (FFA). Thioesterases (eg tesA) hydrolyze thioester bonds, which occur between acyl and ACP chains via sulfhydryl bonds.

[0020] Figure 3 illustrates the structure and function of the enzyme complex acetyl-CoA carboxylase (accABCD). BirA biotinyl accB, the carboxyl-biotin carrier protein, which is part of the acetyl-CoA carboxylase enzyme complex.

[0021] Figure 4 presents an overview of an exemplary biosynthetic trajectory for the production of fatty alcohol starting with acyl-ACP, in which the production of fatty aldehyde is catalyzed by the enzymatic activity of acyl-ACP reductase (AAR) or thioesterase ( TE) and carboxylic acid reductase (Car). Fatty aldehyde is converted to fatty alcohol by aldehyde reductase (also called alcohol dehydrogenase).

[0022] Figure 5 presents an overview of two exemplary biosynthetic pathways for the production of fatty esters starting with acyl-ACP, in which the production of fatty esters is achieved by a one-enzyme system or a three-enzyme system.

[0023] Figure 6 presents an overview of exemplary biosynthetic trajectories for the production of hydrocarbons starting with acyl-ACP; whereas the production of internal olefins is catalyzed by the enzymatic activity of OleABCD; the production of alkanes is catalyzed by the enzymatic conversion of fatty aldehydes to alkanes by means of aldehyde decarbonylase (ADC); and the production of terminal olefins is catalyzed by the enzymatic conversion of fatty acids to terminal olefins by a decarboxylase.

[0024] Figure 7 illustrates the production of the fatty acid derivative (Total Fatty Species) by E. coli strain MG1655 with the fadE gene attenuated (i.e., deleted) compared to the production of the fatty acid derivative by E. coli MG1655. The data presented in Figure 7 show that attenuation of the fadE gene did not affect fatty acid derivative production.

[0025] Figure 8 shows levels of malonyl-CoA in DAM1_i377 in logarithmic phase, which expresses eight different C. glutamicum acetyl-CoA carboxylase (Acc) operon constructs.

[0026] Figure 9 shows intracellular levels of short chain CoA in E. coli DAM1_i377 at logarithmic phase expressing ptrc1/3_accDACB-birA±panK operon constructs. accDACB+birA is also referred to in this document as accD+.

[0027] Figure 10 shows the production of fatty acid methyl ester (FAME) in E. coli strain DV2 expressing ester synthase 9 from M. hydrocarbonoclasticus and components of an acetyl-CoA carboxylase complex from C. glutamicum.

[0028] Figure 11 shows the production of fatty alcohols by E. coli expressing the Synechococcus elongatus PCC7942 AAR together with the accD+ operon from C. glutamicum in a pCL plasmid. Triplicate samples are shown for accD+ strains.

[0029] Figures 12A and 12B show data for the production of total fatty species (mg/l) from duplicate plaque assays when the pCL_Ptrc_tesA plasmid was transformed into each of the iFAB-containing strains shown in the Figures and a fermentation was performed in FA2 medium for 20 hours, from induction to harvest, both at 32 °C (Figure 12A) and at 37 °C (Figure 12B).

[0030] Figure 13 shows the production of FAME with E. coli DAM1 with plasmid pDS57 and with integrated fabHI operons. The fabH/I genes are from Marinobacter aquaeoli VT8 or from Acinetobacter baylyi ADP1. See Table 7 for more details on fabH/I operons in these strains.

[0031] Figure 14 shows the production of FAME with E. coli DAM1 with plasmid pDS57 and different configurations of the C. glutamicum acc genes as well as the integrated fabHI operons. The strains contain the Rhodococcus opacus or Acinetobacter baylyi ADP1 fabH/I genes. See Table 7 for details on the fabH/I and acc operons.

[0032] Figure 15 shows FAME and FFA titers of the two E. coli DAM1 pDS57 strains with integrated fabH/I gene strains selected from Figure 13 compared to the control E. coli DAM1 pDS57 strain.

[0033] Figure 16 is a diagrammatic depiction of the iFAB138 locus including a diagram of the cat-loxP-PT5 cassette integrated in front of iFAB138 (Figure 16A); and a diagram of the PT5_iFAB138 region (Figure 16B).

[0034] Figure 17 shows that strain V668, which has the lph and ilvG genes matched, produced a higher level of FFA than EG149, which has neither of the genes matched.

[0035] Figure 18 is a diagrammatic depiction of a transposon cassette insert in the yijP gene of strain LC535 (transposon placement 68F11). Promoters internal to the transposon cassette are shown and may have effects on adjacent gene expression.

[0036] Figure 19 illustrates the production of fatty alcohol by E. coli DV2 that expresses Synechococcus elongatus acyl-ACP reductase (AAR) and that co-expresses various cyanobacterial acyl-carrying proteins (ACPs). Details regarding the source of the ACPs are provided in Table 12.

[0037] Figure 20 illustrates fatty acid production with E. coli DV2 expressing E. coli tesA thioesterase without leader sequence and co-expressing a cyanobacterial acyl-carrying protein (cACP) and B. subtilis sfp.

DETAILED DESCRIPTION Overview

[0038] The disclosure is based, at least in part, on the finding that modification of various aspects of the fatty acid biosynthetic pathway in a recombinant host cell facilitates enhanced production of fatty acid derivatives by the host cell. The disclosure relates to compositions of fatty acid derivatives that have desirable characteristics and to methods of producing the same. Furthermore, the disclosure relates to recombinant host cells (e.g., microorganisms), cultures of recombinant host cells, methods of producing and using the recombinant host cells, e.g., the use of cultured recombinant host cells in the fermentative production of derivatives of fatty acid that have desirable characteristics.

[0039] More specifically, the production of a desired composition derived from fatty acid (e.g. acyl-CoA, fatty acids, fatty aldehydes, long and short chain alcohols, hydrocarbons, fatty alcohols, esters (e.g. waxes, esters) fatty acids, or fatty esters), terminal olefins, internal olefins and ketones is accentuated by modifying the expression of one or more genes involved in a biosynthetic pathway for the production, degradation and/or secretion of fatty acid, fatty ester, alkane, alkene, olefin, or fatty alcohol. The disclosure provides recombinant host cells that have been engineered to provide enhanced fatty acid biosynthesis relative to non-engineered or native host cells (eg, wild-type host cells that function as control cells), which is achieved, for example, through improvements in the strain. Thus, the disclosure identifies useful polynucleotides for recombinant host cells, the methods s and the compositions of the revelation. It will be generally recognized that absolute sequence identification of such polynucleotides is not necessary. For example, changes to a particular polynucleotide sequence can be made and the encoded polypeptides can be screened for activity. Such changes typically comprise conservative mutations and silent mutations (eg, a codon enhancement). Genetically engineered or modified polynucleotides and encoded variant polypeptides can be screened for a desired function including, but not limited to, increased catalytic activity, increased stability, or decreased inhibition (e.g., decreased feedback inhibition) using known methods. in the technique.

[0040] The disclosure identifies enzymatic activities involved in various steps (i.e., reactions) of the fatty acid biosynthetic pathways described herein under the Enzyme Classification (EC) number and provides exemplary polypeptides (e.g., enzymes) categorized by such EC numbers and exemplary polynucleotides encoding such polypeptides. Such exemplary polypeptides and polynucleotides, which are identified herein by Accession Numbers and/or Sequence Identification Numbers (SEQ ID Nos.), are useful for designing fatty acid pathways in parental host cells to obtain the recombinant host cells. described in this document. The polypeptides and polynucleotides described herein are exemplary and not limiting. Exemplary polypeptide homolog sequences described herein are available to those skilled in the art through various databases (e.g. rhw Entrez databases provided by the National Center for Biotechnology Information (NCBI), ExPasy databases provided by the Swiss Institute of Bioinformatics, the BRENDA database provided by the Technical University of Braunschweig and the KEGG database provided by the Bioinformatics Center at Kyoto University and the University of Tokyo, all of which are available on the Internet).

DEFINITIONS

[0041] As used in this specification and the appended claims, the singular forms "a", "an", "the", and "a" include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to "a recombinant host cell" includes two or more such recombinant host cells, a reference to "a fatty alcohol" includes one or more fatty alcohols or mixtures of fatty alcohols, a reference to "a coding sequence of nucleic acid" includes one or more nucleic acid coding sequences, a reference to "an enzyme" includes one or more enzymes, and the like.

[0042] Accession Numbers: The Sequence Accession Numbers throughout this description were obtained from databases provided by the NCBI (National Center for Biotechnology Information), maintained by the National Institutes of Health, USA (which are identified in the herein the "NCBI Accession Numbers" or alternatively as "GenBank Accession Numbers") and from the UniProt Knowledgebase (UniProtKB) and from the Swiss-Prot database provided by the Swiss Institute of Bioinformatics (which are identified herein as "Numbers of UniProtKB Access").

[0043] Enzyme Classification (EC) Numbers: EC numbers are established by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB), of which the description is available on the IUBMB Enzyme Nomenclature website. EC numbers classify enzymes according to the reaction they catalyze.

[0044] As used herein, the term "nucleotide" refers to a monomeric unit of a polynucleotide consisting of a heterocyclic base, a sugar and one or more phosphate groups. Naturally occurring bases (guanine (G), adenine (A), cytosine (C), thymine (T) and uracil (U)) are typically derived from purine or pyrimidine, although it should be noted that naturally occurring base analogues and unnatural are also included. The naturally occurring sugar is pentose (five carbon sugar) deoxyribose (which forms DNA) or ribose (which forms RNA), although it should be understood that naturally occurring and non-naturally occurring sugar analogues are also included. Nucleic acids are typically joined via phosphate bonds to form nucleic acids or polynucleotides, although many other bonds are known in the art (e.g., phosphorothioates, boranophosphates, and the like).

[0045] As used herein, the term "polynucleotide" refers to a polymer of ribonucleotides (RNA) or deoxyribonucleotides (DNA) which may be single-stranded or double-stranded and which may contain unnatural or altered nucleotides. The terms "polynucleotide", "nucleic acid sequence" and "nucleotide sequence" are used interchangeably herein to refer to a polymeric form of nucleotides of any length, both RNA and DNA. These terms refer to the primary structure of the molecule and thus include single-stranded and double-stranded DNA and single-stranded and double-stranded RNA. The terms include, as equivalents, both RNA and DNA analogs made from nucleotide analogs and modified polynucleotides such as, but not limited to, methylated and/or capped polynucleotides. The polynucleotide can be in any form including but not limited to plasmid, viral, chromosomal, EST, cDNA, mRNA and rRNA.

[0046] As used herein, the terms "polypeptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues. The term "recombinant polypeptide" refers to a polypeptide that is produced by recombinant techniques, whereby a DNA or RNA encoding the expressed protein is generally inserted into a suitable expression vector which is in turn used to transform a host cell to produce the polypeptide.

[0047] As used herein, the term "homolog" refers to a polynucleotide or a polypeptide that comprises a sequence that is at least about 50% identical to the corresponding polynucleotide or polypeptide sequence. Preferred homologous polynucleotides or polypeptides have polynucleotide sequences or amino acid sequences that are at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least about 99% homology to the corresponding amino acid sequence or polynucleotide sequence. As used herein, the terms sequence "homology" and sequence "identity" are used interchangeably.

[0048] A person of ordinary skill in the art is well informed about methods for determining homology between two or more sequences. Briefly, "homology" calculations between two sequences can be performed as follows. Sequences are aligned for improved comparison purposes (for example, gaps may be introduced in one or both of a first and second amino acid or nucleic acid sequences for improved alignment and non-homologous sequences may be ignored for comparison purposes). In a preferred embodiment, the length of a first sequence that is aligned for purposes of comparison is at least about 30%, preferably at least about 40%, more preferably at least about 50%, even more preferably at least about 50%. 60% and even more preferably at least about 70%), at least about 75%, at least about 80%, at least about 85%, at least about 90%), at least about 95%, or approximately 100% of the length of a second string. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions of the first and second sequences are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percentage of homology between the two sequences is a function of the amount of identical positions shared by the sequences, taking into account the amount of gaps and the length of each gap that needs to be introduced for the improved alignment of the two sequences.

[0049] Sequence comparison and determination of percent homology between two sequences can be accomplished using a mathematical algorithm such as BLAST (Altschul et al., J. Mol. Biol, 215(3): pages 403 to 410 (1990)). The percentage of homology between two amino acid sequences can also be determined using the Needleman and Wunsch algorithms that have been incorporated into the GAP program in the GCG software package, using a Blossum 62 matrix or a PAM250 matrix and a weight of range of 16, 14, 12, 10, 8, 6 or 4 and a length weight of 1, 2, 3, 4, 5 or 6 (Needleman and Wunsch, J. Mol. Biol., 48: pages 444 to 453 (1970)). The percentage of homology between two nucleotide sequences can also be determined using the GAP program in the GCG software package, using an NWSgapdna.CMP matrix and an interval weight of 40, 50, 60, 70 or 80 and a length weight of 1, 2, 3, 4, 5 or 6. A person of ordinary skill in the art can perform initial homology calculations and adjust algorithm parameters accordingly. A preferred set of parameters (and one that a practitioner should use if uncertain about which parameters should be applied to determine whether a molecule is within a claims homology limitation) is a Blossum 62 score matrix with a range penalty of 12, a gap extension penalty of 4 and a reading frame gap penalty of 5. Additional methods of sequence alignment are known within biotechnology techniques (see, for example, Rosenberg, BMC Bioinformatics, 6: 278 ( 2005); Altschul, et al., FEBS J., 272(20): pages 5101 to 5109 (2005)).

[0050] As used herein, the term "hybridizes under conditions of low stringency, medium stringency, high stringency, or very high stringency" describes conditions for hybridization and washing. Guidance for carrying out hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1 to 6.3.6. Aqueous and non-aqueous methods are described in this reference and both methods can be used. Specific hybridization conditions referred to herein are as follows: 1) Low stringency hybridization conditions - 6-fold concentrated sodium chloride/sodium citrate (SSC) at approximately 45°C, then two washes in 0.2 SSC once concentrated, 0.1% SDS at least at 50°C (wash temperature can be increased to 55°C for low stringency conditions); 2) Hybridization conditions at medium stringency ~ 6-fold concentrated SSC at approximately 45°C, then one or more washes in 0.2-fold concentrated SSC, 0.1% SDS at 60°C; 3) High stringency hybridization conditions at approximately 6-fold concentrated SSC at approximately 45°C, then one or more washes in 0.2-fold concentrated SSC, 0.1% SDS at 65°C; and 4) Very high stringency hybridization conditions - 0.5M sodium phosphate, 7% SDS at 65°C, then one or more washes in 0.2-fold concentrated SSC, 1% SDS at 65°C . Very high stringency conditions (4) are preferred conditions unless otherwise specified.

[0051] An "endogenous" polypeptide refers to a polypeptide encoded by the host cell genome (eg, the mother microbial cell) from which the recombinant cell is designed or derived.

[0052] An "exogenous" polypeptide refers to a polypeptide that is not encoded by the genome of the microbial mother cell. A variant (ie, mutant) polypeptide is an example of an exogenous polypeptide.

[0053] The term "heterologous" generally means derived from a different species or derived from a different organism. As used herein, it refers to a nucleotide sequence or a polypeptide sequence that is not naturally present in a particular organism. Heterologous expression means that a protein or polypeptide is experimentally added to a cell that does not normally express that protein. Thus, heterologous refers to the fact that a transferred protein was initially derived from a different type of cell or a different species than the recipient. For example, a polynucleotide sequence endogenous to a plant cell can be introduced into a bacterial host cell by recombinant methods and the plant polynucleotide is then a heterologous polynucleotide in a recombinant bacterial host cell.

[0054] As used herein, the term "fragment" of a polypeptide refers to a smaller portion of a full-length polypeptide or protein that varies in size from four amino acid residues to the entire amino acid sequence minus one amino acid residue. . In certain embodiments of the disclosure, a fragment refers to the entire amino acid sequence of a domain of a polypeptide or protein (e.g., a substrate-binding domain or a catalytic domain).

[0055] As used herein, the term "mutagenesis" refers to a process by which the genetic information of an organism is altered in a stable manner. Mutagenesis of a nucleic acid sequence encoding a protein produces a mutant protein. Mutagenesis also refers to changes in non-coding nucleic acid sequences that result in modified protein activity.

[0056] As used herein, the term "gene" refers to nucleic acid sequences that encode either an RNA product or a protein product, it also refers to operably linked nucleic acid sequences that affect expression RNA or protein (e.g., such sequences include but are not limited to promoter or enhancer sequences) or operably linked nucleic acid sequences that encode sequences that affect RNA or protein expression (e.g., such sequences include but not limited to ribosome binding sites or translational control sequences).

[0057] Expression control sequences are known in the art and include, for example, promoters, enhancers, polyadenylation signals, transcriptional terminators, internal ribosome entry sites (IRES) and the like, which provide expression of the sequence of polynucleotides in a host cell. Expression control sequences specifically interact with cellular proteins involved in transcription (Maniatis et al., Science, 236: pages 1237 to 1245 (1987)). Exemplary expression control sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology, Vol. 185, Academic Press, San Diego, Calif. (nineteen ninety).

[0058] In the methods of the disclosure, an expression control sequence is operably linked to a polynucleotide sequence. By "operably linked" is meant that a polynucleotide sequence and one or more expression control sequences are linked in a way that allows for gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are linked to one or more expression control sequences. Operably linked promoters are located upstream of the polynucleotide sequence selected in terms of the direction of transcription and translation. Operably linked enhancers can be located upstream, within, or downstream of the selected polynucleotide.

[0059] As used herein, the term "vector" refers to a nucleic acid molecule capable of carrying another nucleic acid, i.e., a sequence of polynucleotides, to which it has been joined. A useful type of vector is an episome (that is, a nucleic acid capable of extrachromosomal replication). Useful vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are joined. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors". In general, expression vectors useful in recombinant DNA techniques are commonly in the form of "plasmids", which generally refers to circular loops of double-stranded DNA that, in their vector form, are not joined to the chromosome. The terms "plasmid" and "vector" are used interchangeably herein, as plasmid is the most commonly used form of vector. However, other forms of expression vectors which serve equivalent functions and which subsequently become known in the art hereby are also included. In some embodiments, a recombinant vector further comprises a promoter operably linked to the polynucleotide sequence. In some embodiments, the promoter is a developmentally regulated, organelle-specific, tissue-specific, inducible, constitutive, or cell-specific promoter. The recombinant vector typically comprises at least one sequence including (a) an expression control sequence operably coupled to the polynucleotide sequence; (b) a selection marker operably coupled to the polynucleotide sequence; (c) a marker sequence operably coupled to the polynucleotide sequence; (d) a purifying chemical moiety operably coupled to the polynucleotide sequence; (e) a secretion sequence operably coupled to the polynucleotide sequence; and (f) a targeting sequence operably coupled to the polynucleotide sequence. In certain embodiments, the nucleotide sequence is stably incorporated into the genomic DNA of the host cell and expression of the nucleotide sequence is under the control of a regulated promoter region. Expression vectors described herein include a polynucleotide sequence described herein in a form suitable for expression of the polynucleotide sequence in a host cell. It will be appreciated by persons skilled in the art that the design of the expression vector may depend on such factors as the choice of host cell to be transformed, the desired level of polypeptide expression, etc. The expression vectors described herein can be introduced into host cells to produce polypeptides, including fusion polypeptides, encoded by the polynucleotide sequences as described herein.

[0060] Expression of genes encoding polypeptides in prokaryotes, eg E. coli, is most commonly performed with vectors that contain constitutive or inducible promoters that direct the expression of both fusion and other polypeptides. Fusion vectors add an amount of amino acids to a polypeptide encoded therein, usually to an amino- or carboxy-terminus of the recombinant polypeptide. Such fusion vectors typically serve one or more of the following three purposes: (1) to increase expression of the recombinant polypeptide; (2) to increase the solubility of the recombinant polypeptide; and (3) to aid in the purification of the recombinant polypeptide by acting as a linker in affinity purification. Commonly, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion chemical moiety with the recombinant polypeptide. This makes it possible to separate the recombinant polypeptide from the fusion chemical moiety after purification of the fusion polypeptide. In certain embodiments, a polynucleotide sequence of the disclosure is operably linked to a promoter derived from bacteriophage T5.

[0061] In certain embodiments, the host cell is a yeast cell and the expression vector is a yeast expression vector. Examples of vectors for expression in S. cerevisiae yeast include pYepSec1 (Baldari et al., EMBO J., 6: pages 229 to 234 (1987)), pMFa (Kurjan et al., Cell, 30: pages 933 to 943 ( 1982)), pJRY88 (Schultz et al., Gene, 54: pages 113 to 123 (1987)), pYES2 (Invitrogen Corp., San Diego, CA) and picZ (Invitrogen Corp., San Diego, CA).

[0062] In other embodiments, the host cell is an insect cell and the expression vector is a baculovirus expression vector. Available baculovirus vectors for the expression of proteins in cultured insect cells (e.g., Sf9 cells) include, for example, the pAc series (Smith et al., Mol. Cell Biol., 3: pages 2156 to 2165 (1983) )) and the pVL series (Lucklow et al., Virology, 170: pages 31 to 39 (1989)).

[0063] In yet another embodiment, the polynucleotide sequences described herein can be expressed in mammalian cells using a mammalian expression vector. Other expression systems suitable for both prokaryotic and eukaryotic cells are well known in the art; see, for example, Sambrook et al., "Molecular Cloning: A Laboratory Manual", second edition, Cold Spring Harbor Laboratory, (1989).

[0064] The term "matching wild-type host cell", as referred to herein, means a cell that functions as a control cell. For example, if a polypeptide in a recombinant host cell is upregulated, then the same polypeptide would exist at a lower level in the control cell. Conversely, if a polypeptide in a recombinant host cell is downregulated, then the same polypeptide would exist at a higher level in the control cell. Furthermore, "recombinant or engineered host cell" is a microorganism used to produce one or more of a fatty acid derivative including, for example, acyl-CoA, fatty acids, fatty aldehydes, long and short chain alcohols, hydrocarbons , fatty alcohols, esters (eg waxes, fatty acid esters or fatty esters), terminal olefins, internal olefins and ketones. In some embodiments, the recombinant host cell comprises one or more polynucleotides, each polynucleotide encoding a polypeptide that has a fatty acid biosynthetic enzyme activity.

[0065] As used herein "acyl-CoA" refers to an acylthioester formed between the carbonyl carbon of the alkyl chain and the sulfhydryl group of the 4'-phosphopantethionyl chemical moiety of coenzyme A (CoA), which has the formula RC( O)S-CoA, where R is any alkyl group having at least 4 carbon atoms.

[0066] As used herein, "acyl-ACP" refers to an acylthioester formed between the carbonyl carbon of the alkyl chain and the sulfhydryl group of the phosphopantetheinyl chemical portion of an acyl carrier protein (ACP). The phosphopantetheinyl chemical moiety is attached post-translationally to a conserved serine residue on an ACP by the action of the acyl-binding holoprotein synthase (ACPS), a phosphopantetheinyl transferase. In some embodiments, an acyl-ACP is an intermediate in the synthesis of fully saturated acyl-ACPs. In other embodiments, an acyl-ACP is an intermediate in the synthesis of unsaturated acyl-ACPs. In some embodiments, the carbon chain will be approximately 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 carbons. Each of these acyl-ACPs are substrates for enzymes that convert them to fatty acid derivatives.

[0067] As used herein, the term "fatty acid derivative" means a "fatty acid" or a "fatty acid derivative" which may be called a "fatty acid or derivative thereof". The term "fatty acid" means a carboxylic acid having the formula RCOOH. R represents an aliphatic group, preferably an alkyl group. R may comprise from approximately 4 to approximately 22 carbon atoms. Fatty acids can be saturated, monounsaturated or polyunsaturated. A "fatty acid derivative" is a product made in part from the biosynthetic pathway of the producing host organism's fatty acid. "Fatty acid derivatives" include products made in part from acyl-ACP or acyl-ACP derivatives. Exemplary fatty acid derivatives include, for example, acyl-CoA, fatty acids, fatty aldehydes, long and short chain alcohols, fatty alcohols, hydrocarbons, esters (e.g. waxes, fatty acid esters or fatty esters), olefins terminals, internal olefins and ketones.

[0068] A "fatty acid derivative composition", as referred to herein, is produced by a recombinant host cell and typically comprises a mixture of fatty acid derivatives. In some cases, the mixture includes more than one type of product (eg, fatty acids and fatty alcohols, fatty acids and fatty acid esters, or alkanes and olefins). In other cases, compositions derived from fatty acids may comprise, for example, a mixture of fatty alcohols (or other fatty acid derivative) with various characteristics of chain length, saturation and branching. In still other cases, the fatty acid derivative composition comprises a mixture of either more than one type of product or products having various characteristics of chain length, saturation, and branching.

[0069] As used herein, the term "fatty acid biosynthetic pathway" means a biosynthetic pathway that produces fatty acids and derivatives thereof. The fatty acid biosynthetic pathway may include additional enzymes or polypeptides with enzymatic activities, in addition to those discussed herein, to produce fatty acid derivatives that have desirable characteristics.

[0070] As used herein, "fatty aldehyde" means an aldehyde having the formula RCHO characterized by a carbonyl group (C=O). In some embodiments, the fatty aldehyde is any aldehyde made from a fatty alcohol. In certain embodiments, the group R has at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, or at least 19, carbons in length. Alternatively or additionally, the group R has 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less less, 9 or less, 8 or less, 7 or less, or 6 or less carbons in length. Thus, the R group may have an R group connected by two of the above endpoints. For example, the R group can be 6 to 16 carbons long, 10 to 14 carbons long, or 12 to 18 carbons long. In some embodiments, the fatty aldehyde is a C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25 fatty aldehyde or C26. In certain embodiments, the fatty aldehyde is a C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, or C18 fatty aldehyde.

[0071] As used herein, "fatty alcohol" means an alcohol having the formula ROH. In some embodiments, the group R has at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, or at least 19 carbons in length. Alternatively or additionally, the group R has 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less less, 9 or less, 8 or less, 7 or less, or 6 or less carbons in length. Thus, the R group can have an R group connected by either of the above two endpoints. For example, the R group can be 6 to 16 carbons long, 10 to 14 carbons long, or 12 to 18 carbons long. In some embodiments, the fatty alcohol is a C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25 fatty alcohol or a C26. In certain embodiments, the fatty alcohol is a C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, or C18 fatty alcohol.

[0072] The R group of a fatty acid derivative, for example a fatty alcohol, can be straight chain or branched chain. Branched chains can have more than one branch point and can include cyclic branches. In some embodiments, the branched fatty acid, branched fatty aldehyde, or branched fatty alcohol is a branched fatty acid, branched fatty aldehyde, or branched fatty alcohol C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16 , C17, C18, C19, C20, C21, C22, C23, C24, C25 or C26. In particular embodiments, the branched fatty acid, branched fatty aldehyde, or branched fatty alcohol is a branched fatty acid, branched fatty aldehyde, or C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, or C18 In certain embodiments, the hydroxyl group of the branched fatty acid, branched fatty aldehyde, or branched fatty alcohol is in the primary (C1) position.

[0073] In certain embodiments, the branched fatty acid derivative is a fatty acid isoderivative, for example a fatty iso-aldehyde, a fatty iso-alcohol, or an anteisoderivative of fatty acid, a fatty anteisoaldehyde or an anteiso- fatty alcohol. In exemplary embodiments, the branched fatty acid derivative is selected from iso-C7:0, iso-C8:0, iso-C9:0, iso-C10:0, iso-C11:0, iso-C12 :0, iso-C13:0, iso-C14:0, iso-C15:0, iso-C16:0, iso-C17:0, iso-C18:0, iso-C19:0, anteiso-C7:0 , anteiso-C8:0, anteiso-C9:0, anteiso-C10:0, anteiso-C11:0, anteiso-C12:0, anteiso-C13:0, anteiso-C14:0, anteiso-C15:0, anteiso -C16:0, anteiso-C17:0, anteiso-C18:0 and an anteiso-C19:0.

[0074] The R group of a branched or unbranched fatty acid derivative can be saturated or unsaturated. If unsaturated, the R group may have one or more than one point of unsaturation. In some embodiments, the unsaturated fatty acid derivative is a monounsaturated fatty acid derivative. In certain embodiments, the unsaturated fatty acid derivative is a C6:1, C7:1, C8:1, C9:1, C10:1, C11:1, C12:1, C13:1, C14 unsaturated fatty acid derivative. :1, C15:1, C16:1, C17:1, C18:1, C19:1, C20:1, C21:1, C22:1, C23:1, C24:1, C25:1, or a C26 :1. In certain embodiments, the unsaturated fatty acid derivative is a C10:1, C12:1, C14:1, C16:1 or C18:1 unsaturated fatty acid derivative. In other embodiments, the unsaturated fatty acid derivative is unsaturated at the omega-7 position. In certain embodiments, the unsaturated fatty acid derivative comprises a cis double bond.

[0075] As used herein, the term "clone" typically refers to a cell or group of cells descended from and genetically essentially identical to a single common ancestor, e.g. bacteria from a cloned bacterial colony have arisen from a single bacterial cell.

[0076] As used herein, the term "culture" typically refers to a liquid medium comprising viable cells. In one embodiment, a culture comprises cells that reproduce in a predetermined culture medium under controlled conditions, for example, a culture of recombinant host cells grown in a liquid medium comprising a selected carbon and nitrogen source. "Growing in culture" or "culturing" refers to growing a population of recombinant host cells under suitable conditions in a liquid or solid medium. In particular embodiments, growth in culture refers to the fermentative bioconversion of a substrate to an end product. Culture growth media are well known and individual components of such culture media are available from commercial sources, for example under the trademarks Difco™ and BBL™. In a non-limiting example, the aqueous nutrient medium is a "rich medium" comprising complex sources of nitrogen, salts and carbon, such as YP medium, which comprises 10 g/l peptone and 10 g/l yeast extract. in such a way. The host cell of a culture can be further engineered to assimilate carbon efficiently and use cellulosic materials as carbon sources in accordance with methods described in US Patents 5,000,000; 5,028,539; 5,424,202; 5,482,846; 5,602,030; WO 2010127318 . Additionally, in some embodiments, the host cell is engineered to express an invertase so that sucrose can be used as a carbon source.

[0077] As used herein, the term "under conditions effective to express a genetically modified polynucleotide sequence" means any condition that allows a host cell to produce a desired fatty acid derivative. Suitable conditions include, for example, fermentation conditions.

[0078] As used herein, an "altered activity level" or "modified" of a protein, e.g. an enzyme, in a recombinant host cell refers to a difference in one or more characteristics in activity determined in relative to the mother or native host cell. Typically, differences in activity are determined between a recombinant host cell, which has a modified activity, and the corresponding wild-type host cell (e.g., a comparison of a culture of a recombinant host cell to a wild-type host cell). corresponding). Modified activities may be the result, for example, of modified amounts of protein expressed by a recombinant host cell (e.g., as the result of an increased or decreased amount of copies of DNA sequences encoding the protein, increased or decreased amount of mRNA transcripts encoding the protein and/or increased or decreased amounts of protein translation of the protein from mRNA); changes in protein structure (e.g., changes in primary structure, such as changes to a protein coding sequence that result in changes in substrate specificity, changes in observed kinetic parameters); and changes in protein stability (e.g., increased or decreased protein degradation). In some embodiments, the polypeptide is a mutant or a variant of any of the polypeptides described herein. In certain cases, the coding sequences for the polypeptides described herein are improved codons for expression in a particular host cell. For example, for expression in E. coli, one or more codons can be improved as described, for example, in Grosjean et al., Gene 18: pages 199 to 209 (1982).

[0079] The term "regulatory sequences", as used herein, typically refers to a sequence of bases in DNA operatively linked to DNA sequences that encode a protein that ultimately controls the expression of the protein. Examples of regulatory sequences include, but are not limited to, RNA promoter sequences, transcription factor binding sequences, transcription termination sequences, transcriptional modulators (such as enhancer elements), nucleotide sequences that affect RNA stability and translational regulatory sequences (such as ribosome binding sites (e.g. Shine-Dalgarno sequences in prokaryotes or Kozak sequences in eukaryotes), initiation codons and termination codons).

[0080] The terms "altered expression level" and "modified expression level" are used interchangeably and mean that a polynucleotide, polypeptide or hydrocarbon is present at a different concentration in an engineered host cell compared to its concentration in a corresponding wild-type cell under the same conditions.

ligada por dois valores quaisquer dentre os antecedentes. Em outras modalidades, um derivado de ácido graxo é produzido em uma titulação de mais do que 100g/l, mais do que 200g/l, mais do que 300g/l ou maior, tal como 500 g/l, 700 g/l, 1.000 g/l, 1.200 g/l, 1.500 g/l ou 2.000 g/l. A titulação preferencial de derivado de ácido graxo produzido por uma célula hospedeira recombinante de acordo com os métodos da revelação é a partir de 5 g/l a 200 g/l, de 10 g/l a 150 g/l, de 20 g/l a 120 g/l e de 30 g/l a 100 g/l. Em uma modalidade, a titulação de derivado de ácido graxo produzido por uma célula hospedeira recombinante de acordo com os métodos da revelação é de aproximadamente 1 g/l a cerca de 250 g/l e mais particularmente de 90 g/l a cerca de 120 g/l. A titulação pode se referir a um derivado particular de ácido graxo ou a uma combinação de derivados de ácido graxo produzidos por uma dada cultura de célula hospedeira recombinante.[0081] As used herein, the term "titer" refers to the amount of fatty acid derivative produced per unit volume of host cell culture. In any aspect of the compositions and methods described herein, a fatty acid derivative is produced in a titration of about 25 mg/l, approximately 50 mg/l, approximately 75 mg/l,

linked by any two values from the antecedents. In other embodiments, a fatty acid derivative is produced at a titration of more than 100g/l, more than 200g/l, more than 300g/l or greater, such as 500g/l, 700g/l, 1,000 g/l, 1,200 g/l, 1,500 g/l or 2,000 g/l. The preferred titration of fatty acid derivative produced by a recombinant host cell according to the methods of the disclosure is from 5 g/l to 200 g/l, from 10 g/l to 150 g/l, from 20 g/l to 120 g/l and from 30 g/l to 100 g/l. In one embodiment, the titer of fatty acid derivative produced by a recombinant host cell according to the methods of the disclosure is from approximately 1 g/l to about 250 g/l and more particularly from 90 g/l to about 120 g/l . Titration may refer to a particular fatty acid derivative or to a combination of fatty acid derivatives produced by a given recombinant host cell culture.

[0082] As used herein, "yield of fatty acid derivative produced by a host cell" refers to the efficiency with which an input carbon source is converted to product (i.e. fatty alcohol or fatty aldehyde) in a host cell. Host cells engineered to produce fatty acid derivatives according to the methods of the disclosure have a yield of at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, or at least 30%, or a range limited by two of the preceding values. In other embodiments, fatty acid derivatives or derivatives are produced in a yield of greater than 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. Alternatively or additionally, the yield is approximately 30% or less, approximately 27% or less, approximately 25% or less, or approximately 22% or less. Thus, throughput can be limited by any of the above endpoints. For example, the yield of fatty acid derivatives or derivatives produced by the recombinant host cell according to the methods of the disclosure may be from 5% to 15%, 10% to 25%, from 10% to 22%, from 15% to 27%, from 18% to 22%, from 20% to 28% or from 20% to 30%. In a particular embodiment, the yield of fatty acid derivatives or derivatives produced by the recombinant host cell is approximately 10% to about 40%. In another particular embodiment, the yield of fatty acid derivatives or derivatives produced by the recombinant host cell is approximately 25%. Yield may refer to a particular fatty acid derivative or a combination of fatty acid derivatives produced by a given recombinant host cell culture.

[0083] As used herein, the term "productivity" refers to the amount of fatty acid derivatives or derivatives produced per unit volume of host cell culture per unit time. In any aspect of the compositions and methods described herein, the productivity of fatty acid derivatives or derivatives produced by a recombinant host cell is at least 100 mg/l/hour, at least 200 mg/l/hour, at least 300 mg/l/hour, at least 400 mg/l/hour, at least 500 mg/l/hour, at least 600 mg/l/hour or at least 2,500 mg/l/hour. For example, the productivity of fatty acid derivatives or derivatives produced by a recombinant host cell according to the methods of the invention can be from 500 mg/l/hour to 2500 mg/l/hour or from 700 mg/hour. l/hour to 2000 mg/l/hour. In a particular embodiment, the yield is from about 0.7 mg/l/h to about 3 g/l/h. Productivity can refer to a particular fatty acid derivative or a combination of fatty acid derivatives produced by a given recombinant host cell culture.

[0084] As used herein, the terms "total fatty species" and "total fatty acid product" may be used interchangeably herein to refer to the amount of fatty alcohols, fatty aldehydes and fatty acids as evaluated by GC-FID as described in International Patent Application WO2008/119082. The same terms can be used to mean fatty esters and free fatty acids when referring to a fatty ester analysis.

[0085] As used herein, the term "glucose utilization rate" means the amount of glucose used by the culture per unit of time, reported as grams/liter/hour (g/l/hr). As used herein, the term "carbon source" refers to a substrate or compound suitable for use as a carbon source for prokaryotic or simple eukaryotic cell growth. Carbon sources can be in a variety of forms including, but not limited to, polymers, carbohydrates, acids, alcohols, aldehydes, ketones, amino acids, peptides, and phases (eg, CO and CO2). Exemplary carbon sources include, but are not limited to, monosaccharides such as glucose, fructose, mannose, galactose, xylose and arabinose; oligosaccharides, such as fructooligosaccharide and galactoligosaccharide; polysaccharides such as starch, cellulose, pectin and xylan; disaccharides such as sucrose, maltose, cellobiose and turanose; cellulosic material and variants such as hemicelluloses, methylcellulose and carboxymethylcellulose; saturated or unsaturated fatty acids, succinate, lactate and acetate; alcohols, such as ethanol, methanol and glycerol, or mixtures thereof. The carbon source may also be a product of photosynthesis, such as glucose. In certain preferred embodiments, the carbon source is biomass. In other preferred embodiments, the carbon source is glucose. In other preferred embodiments the carbon source is sucrose.

[0086] As used herein, the term "biomass" refers to any biological material from which a carbon source is derived. In some embodiments, a biomass is processed and becomes a source of carbon, which is suitable for bioconversion. In other embodiments, the biomass does not require further processing to become a carbon source. The carbon source can be converted and become a biofuel. An exemplary biomass source is plant matter or vegetation, such as corn, sugar cane or Panicum virgatum. Another exemplary source of biomass is metabolic waste products such as animal matter (e.g. cow manure). In addition, exemplary sources of biomass include algae and other marine plants. Biomass may also include industrial, agricultural, forestry and household waste products including, but not limited to, fermentation residues, silage, straw, firewood, sewage waste, garbage, cellulosic municipal waste and food scraps. The term "biomass" also refers to carbon sources such as carbohydrates (eg, monosaccharides, disaccharides or polysaccharides).

[0087] As used herein, the term "isolated", with respect to products (such as fatty acids and derivatives thereof), refers to products that are separated from cellular components, cell culture media, or of chemical or synthetic precursors. Fatty acids and derivatives thereof produced by the methods described herein may be relatively immiscible in the fermentation broth as well as in the cytoplasm. Therefore, fatty acids and their derivatives can be collected in an organic phase both intracellularly and extracellularly.

[0088] As used herein, the terms "purify", "purified" and "purification" mean the removal or isolation of a molecule from its environment, for example, by isolation or separation. "Substantially purified" molecules are at least about 60% free (e.g., at least about 70% free, at least about 75% free, at least about 85% free, at least about 90% free, at least about 95% free, at least about 97% free, at least about 99% free) from other components with which they are associated. As used herein, these terms also refer to removing contaminants from a sample. For example, removing contaminants can result in an increase in the percentage of fatty acid derivatives in a sample. For example, when a fatty acid derivative is produced in a recombinant host cell, the fatty acid derivative can be purified by removing host cell proteins. After purification, the percentage of fatty acid derivative in the sample is increased. The terms "purify", "purified" and "purification" are relative terms that do not require absolute purity. Thus, for example, when a fatty acid derivative is produced in recombinant host cells, a purified fatty acid derivative is a fatty acid derivative that is substantially separated from other cellular components (e.g., nucleic acids, polypeptides, lipids, carbohydrates). or other hydrocarbons).

IMPROVEMENTS IN CEPA

[0089] In order to generate a high titer, yield, and/or productivity of fatty acid derivatives, several modifications have been made to the production of host cells. FadR is a key regulatory factor involved in fatty acid degradation and fatty acid biosynthetic pathways (Cronan et al, Mol Microbiol, 29(4): pages 937 to 943 (1998)). The E. Coli ACS enzyme FadD and the fatty acid transport protein FadL are components of a fatty acid uptake system. FadL mediates the transport of fatty acids into the bacterial cell and FadD mediates the formation of acyl-CoA esters. When no other carbon source is available, exogenous fatty acids are taken up by bacteria and converted into acyl-CoA esters, which can bind to the transcription factor FadR and depress the expression of fad genes that encode the proteins responsible for transport (FadL ), activation (FadD), and β-oxidation (FadA, FadB, FadE and FadH) of fatty acid. When alternative carbon sources are available, bacteria synthesize fatty acids as acyl-ACPs, which are used for phospholipid synthesis but are not substrates for e-oxidation. Thus, acyl-CoA and acyl-ACP are both independent sources of fatty acids that can result in different end products (Caviglia et al, J Biol. Chem., 279(12): pages 1163 to 1169 (2004)).

[0090] There are conflicting speculations in the art as to factors that may limit fatty acid biosynthesis in host cells such as E. coli. One suggestion is that a limitation of the main precursors for fatty acid biosynthesis, eg acetyl-CoA and malonyl-CoA, may result in decreased synthesis of fatty acid derivatives. One approach to increasing the flux through fatty acid biosynthesis is to manipulate various enzymes along the way (see Figures 1 and 2). Example 3 describes studies showing the construction of fab operons encoding enzymes on the biosynthetic pathway for the conversion of malonyl-CoA to acyl-ACPs and for integration into a chromosome of an E. coli host cell. With no desire to be bound by theory, this can increase the flow of fatty acid biosynthesis. The delivery of acyl-ACPs from acetyl-CoA through the acetyl-CoA carboxylase (acc) complex and the fatty acid (fab) biosynthetic pathway is another step that can limit the rate of fatty acid derivative production (see Figure 3). Example 2 shows that the overexpression effect of an improved version of accABCD (±birA) from E. coli Corynebacterium glutamicum demonstrated that such genetic modifications can lead to increased production of acetyl-CoA and malonyl-CoA in E. coli.

[0091] In another approach, mutations in the rph and ilvG genes in the E. coli host cell were shown to result in increased production of free fatty acids (FFA), which translated into increased production of fatty alcohol as shown in Example 4. In yet another approach, transposon mutagenesis and high-throughput screening added value towards finding beneficial mutations that increase titer or yield. As shown in Example 5, a transposon insertion into the yijP gene can improve the yield of fatty alcohol in shake flask and fed-batch fermentations.

Generation of Fatty Acid Derivatives by Recombinant Host Cells

[0092] The present disclosure provides numerous examples of polypeptides (i.e., enzymes) that have activities suitable for use in the fatty acid biosynthetic pathways described herein. Such polypeptides are collectively referred to herein as "fatty acid biosynthetic polypeptides" or "fatty acid biosynthetic enzymes". Non-limiting examples of fatty acid pathway polypeptides suitable for use in recombinant host cells of the disclosure are provided herein. In some embodiments, the disclosure includes a recombinant host cell including a polynucleotide sequence that encodes a fatty acid biosynthetic polypeptide. The polynucleotide sequence, which includes an open reading frame encoding a fatty acid biosynthetic polypeptide and operably linked regulatory sequences, can be integrated into a chromosome of the recombinant host cells, incorporated into one or more resident plasmid expression systems. in the recombinant host cell, or both. In one embodiment, a biosynthetic fatty acid polynucleotide sequence encodes a polypeptide that is endogenous to the parent host cell (i.e., the control cell) of the recombinant host cell being engineered. Some such endogenous polypeptides are overexpressed in the recombinant host cell. In another embodiment, the fatty acid biosynthetic polynucleotide sequence encodes an exogenous or heterologous polypeptide. In other words, the polypeptide encoded by the polynucleotide is exogenous to the host host cell. In yet another embodiment, the genetically modified host cell overexpresses a gene encoding a polypeptide (protein) that increases the rate at which the host cell produces the substrate of a biosynthetic fatty acid enzyme, i.e., a fatty acylthioester substrate. In certain embodiments, the enzyme encoded by the expressed gene is directly involved in fatty acid biosynthesis. Such recombinant host cells can be further engineered to include a polynucleotide sequence that encodes one or more fatty acid biosynthetic polypeptides (i.e., enzymes involved in fatty acid biosynthesis). Examples of such polypeptides are polypeptides or proteins that have thioesterase activity, whereby the recombinant host cell synthesizes fatty acids; or that have thioesterase activity and carboxylic acid reductase (CAR) activity, with the recombinant host cell synthesizing fatty aldehydes and fatty alcohols; or which have thioesterase activity, carboxylic acid reductase activity and alcohol dehydrogenase activity whereby the recombinant host cell synthesizes fatty alcohols; or that have acyl-CoA reductase (AAR) activity and the recombinant host cell synthesizes fatty aldehydes and fatty alcohols; or that have acyl-CoA reductase (AAR) activity and alcohol dehydrogenase activity with the recombinant host cell synthesizing fatty alcohols; or that have fatty alcohol acyl-CoA reductase (FAR) activity, with the recombinant host cell synthesizing fatty alcohols; or which have thioesterase activity, carboxylic acid reductase activity, and aldehyde decarbonylase activity, with the recombinant host cell synthesizing alkanes; or which have acyl-CoA reductase activity and aldehyde decarbonylase activity, with the recombinant host cell synthesizing alkanes; or which has ester synthase activity where the recombinant host cell synthesizes fatty esters (eg, an enzyme system; see Figure 5); or that have thioesterase activity, acyl-CoA synthase activity, and ester synthase activity with the recombinant host cell synthesizing fatty esters (eg, three enzyme system; see Figure 5); or which has OleA activity, wherein the recombinant host cell synthesizes aliphatic ketones; or which has OleABCD activity, wherein the recombinant host cell synthesizes internal olefins; or which has thioesterase activity and decarboxylase activity, wherein the recombinant host cell synthesizes terminal olefins; or combinations thereof. In some embodiments, at least one polypeptide encoded by a fatty acid biosynthetic polynucleotide is an exogenous (or heterologous) polypeptide (e.g., a polypeptide that originates from an organism other than the parent host cell, or a variant of a polypeptide native to the microbial mother cell) or an endogenous polypeptide (i.e., a polypeptide native to the mother host cell) wherein the endogenous polypeptide is overexpressed in the recombinant host cell.

[0093] Table 1 below provides a listing of exemplary proteins that can be expressed in recombinant host cells to facilitate the production of particular fatty acid derivatives. Table 1: Gene Nomenclatures

Production of Fatty Acids

[0094] Recombinant host cells may include one or more polynucleotide sequences that comprise an open reading frame encoding a thioesterase, e.g. that have an EC 3.1.1.5 or EC 3.1.2.- Enzyme Commission number ( for example, EC 3.1.2.14), together with operably linked regulatory sequences that facilitate expression of the protein in recombinant host cells. In recombinant host cells, the open reading frame encoding the regulatory sequences and/or sequences is modified with respect to the corresponding wild-type gene encoding thioesterase. The thioesterase activity in the recombinant host cell is modified relative to the thioesterase activity expressed from the corresponding wild-type gene in a corresponding host cell. In some embodiments, a fatty acid derivative composition that includes fatty acids is produced by growing a recombinant cell in culture in the presence of a carbon source under conditions effective to express the thioesterase. In related embodiments, the recombinant host cell comprises a polynucleotide that encodes a polypeptide that has thioesterase activity and one or more additional polynucleotides that encode polypeptides that have other fatty acid biosynthetic enzyme activities. In some such cases, the fatty acid produced by the action of thioesterase is converted by one or more enzymes that have a different fatty acid biosynthetic enzyme activity to another fatty acid derivative, such as, for example, a fatty ester, fatty aldehyde , fatty alcohol or a hydrocarbon.

[0095] The chain length of a fatty acid, or a fatty acid derivative made therefrom, can be selected by modifying the expression of particular thioesterases. Thioesterase will influence the chain length of fatty acid derivatives produced. The chain length of a fatty acid derivative substrate can be selected by modifying the expression of selected thioesterases (EC 3.1. 2.14 or EC 3.1.1.5). Therefore, host cells can be engineered to express, overexpress, have attenuated expression, or not express one or more selected thioesterases to enhance production of a preferred fatty acid derivative substrate. For example, C10 fatty acids can be produced by expressing a thioesterase that has a preference for producing C10 fatty acids, and attenuating thioesterases that have a preference for producing fatty acids other than C10 fatty acids (e.g., a thioesterase that prefers to produce C14 fatty acids). This would result in a relatively homogeneous population of fatty acids that have a carbon chain length of 10. In other cases, C14 fatty acids can be produced by attenuating endogenous thioesterases that produce non-C14 fatty acids and expressing the thioesterases that use C14-ACP. In some situations, C12 fatty acids can be produced by expressing thioesterases that use C12-ACP and attenuating thioesterases that produce non-C12 fatty acids. For example, C12 fatty acids can be produced by expressing a thioesterase that has a preference for producing C12 fatty acids and attenuating thioesterases that have a preference for producing fatty acids other than C12 fatty acids). This would result in a relatively homogeneous population of fatty acids that have a carbon chain length of 12. Fatty acid derivatives are recovered from the culture medium with substantially all of the fatty acid derivatives produced extracellularly. The fatty acid derivative composition produced by a recombinant host cell can be analyzed using methods known in the art, e.g. GC-FID, in order to determine the distribution of particular fatty acid derivatives as well as determine lengths of chain and degree of saturation of the components of the fatty acid derivative composition. Overproduction of acetyl-CoA, malonyl-CoA and fatty acid can be verified using methods known in the art, for example, by using radioactive precursors, HPLC, or GC-MS subsequent to cell lysis. Additional non-limiting examples of thioesterases and polynucleotides encoding them for use in the fatty acid pathway are provided in PCT Publication Application No WO2010/075483, expressly incorporated by reference herein.

Production of Fatty Aldehydes

[0096] In one embodiment, the recombinant host cell produces a fatty aldehyde. In some embodiments, a fatty acid produced by the recombinant host cell is converted to a fatty aldehyde. In some embodiments, the fatty aldehyde produced by the recombinant host cell is then converted to a fatty alcohol or a hydrocarbon. In some embodiments, native (endogenous) fatty aldehyde biosynthetic polypeptides, such as aldehyde reductases, are present in the host cell (eg, E. coli) and are effective in converting fatty aldehydes to fatty alcohols. In other embodiments, a native (endogenous) fatty aldehyde biosynthesizing polypeptide is overexpressed. In still other embodiments, an exogenous fatty aldehyde biosynthesizing polypeptide is introduced into a recombinant host cell and expressed or overexpressed. A recombinant host or native cell may comprise a polynucleotide that encodes an enzyme that has fatty aldehyde biosynthetic activity (e.g., a fatty aldehyde biosynthetic polypeptide or a fatty aldehyde biosynthetic polypeptide or enzyme). A fatty aldehyde is produced when the fatty aldehyde biosynthetic enzyme is expressed or overexpressed in the host cell. A recombinant host cell engineered to produce a fatty aldehyde will typically convert some of the fatty aldehyde to a fatty alcohol. In some embodiments, a fatty aldehyde is produced by expressing or overexpressing in the recombinant host cell a polynucleotide that encodes a polypeptide that has fatty aldehyde biosynthetic activity such as carboxylic acid reductase (CAR) activity. CarB is an exemplary carboxylic acid reductase. In practicing the disclosure, a gene encoding a carboxylic acid reductase polypeptide can be expressed or overexpressed in the host cell. In some embodiments, the CarB polypeptide has the amino acid sequence of SEQ ID NO: 7. In other embodiments, the CarB polypeptide is a variant or mutant of SEQ ID NO: 7. Examples of carboxylic acid reductase (CAR), the polypeptides and polynucleotides encoding them include, but are not limited to, FadD9 (EC 6.2.1.-, UniProtKB Q50631, GenBank NP_217106, SEQ ID NO: 34), CarA (GenBank ABK75684), CarB (GenBank YP889972; SEQ ID NO: 33) and related polypeptides described in PCT Publication No. WO2010/042664 and in US Patent No. 8,097,439, both of which are expressly incorporated by reference herein. In some embodiments the recombinant host cell further comprises a polynucleotide encoding a thioesterase. In some embodiments, the fatty aldehyde is produced by expressing or overexpressing in the recombinant host cell a polynucleotide that encodes a fatty aldehyde biosynthetic polypeptide, such as a polypeptide that has acyl-ACP reductase (AAR) activity. Expression of acyl-ACP reductase in a recombinant host cell results in the production of fatty aldehydes and fatty alcohols (see Figure 4). Native (endogenous) aldehyde reductases present in a recombinant host cell (eg, E. coli) can convert fatty aldehydes to fatty alcohols. Exemplary acyl-ACP reductase polypeptides are described in PCT Publications Nos. WO2009/140695 and WO/2009/140696, both of which are expressly incorporated by reference herein. A composition comprising fatty aldehydes (a fatty aldehyde composition) is produced by growing a host cell in culture in the presence of a carbon source under conditions effective to express the fatty aldehyde biosynthesizing enzyme. In some embodiments, the fatty aldehyde composition comprises fatty aldehydes and fatty alcohols. Typically, the fatty aldehyde composition is recovered from the extracellular environment of the recombinant host cell, i.e., from the cell culture medium. Production of Fatty Alcohols

[0097] In some embodiments, the recombinant host cell includes a polynucleotide that encodes a polypeptide (an enzyme) that has fatty alcohol biosynthetic activity (a fatty alcohol biosynthetic polypeptide or a fatty alcohol biosynthetic enzyme) and a fatty alcohol is produced by the recombinant host cell. A composition comprising fatty alcohols (a fatty alcohol composition) can be produced by growing the recombinant host cell in culture in the presence of a carbon source under conditions effective to express a fatty alcohol biosynthesizing enzyme. In some embodiments, the fatty alcohol composition comprises fatty alcohols, however, a fatty alcohol composition may comprise other fatty acid derivatives. Typically, the fatty alcohol composition is recovered from the extracellular environment of the recombinant host cell, i.e., from the cell culture medium. In one approach, recombinant host cells were engineered to produce fatty alcohols by expressing a thioesterase, which catalyzes the conversion of acyl-ACPs to free fatty acids (FFAs) and a carboxylic acid reductase (CAR), which converts fatty acids into free fatty acids (FFAs). free fatty aldehydes. Native (endogenous) aldehyde reductases present in the host cell (eg, E. coli) can convert fatty aldehydes to fatty alcohols. In some embodiments, native (endogenous) fatty aldehyde biosynthetic polypeptides, such as aldehyde reductases, are present in the host cell and may be sufficient to convert fatty aldehydes to fatty alcohols. However, in other embodiments, a native (endogenous) fatty aldehyde biosynthetic polypeptide is overexpressed, and in still other embodiments, an exogenous fatty aldehyde biosynthetic polypeptide is introduced into a recombinant host cell and expressed or overexpressed. In some embodiments, the fatty alcohol is produced by expressing or overexpressing in the recombinant host cell a polynucleotide that encodes a polypeptide that has fatty alcohol biosynthesizing activity that converts a fatty aldehyde to a fatty alcohol. For example, an alcohol dehydrogenase (aldehyde reductase, eg EC 1.1.1.1), can be used when practicing disclosure. As used herein, an alcohol dehydrogenase refers to a polypeptide capable of catalyzing the conversion of a fatty aldehyde to an alcohol (eg, a fatty alcohol). One of ordinary skill in the art will appreciate that certain alcohol dehydrogenases have the ability to catalyze other reactions as well and that these non-specific alcohol dehydrogenases are also encompassed by alcohol dehydrogenase. Examples of alcohol dehydrogenase, useful polypeptides according to the disclosure include, but are not limited to, AlrA from Acinetobacter sp. M-1 (SEQ ID NO: 3) or AlrA homologs such as AlrAadpl (SEQ ID NO: 4) and E. coli endogenous alcohol dehydrogenases such as YjgB, (AAC77226) (SEQ ID NO: 5), DkGA (NP_417485), DkgB (NP_414743), YdjL (AAC74846), YdjJ (NP_416288), AdhP (NP_415995), YhdH (NP_417719), YahK (NP_414859), YphC (AAC75598), YqhD (446856) and YbbO [AAC7595. . Additional examples are described in International Patent Applications WO 2007/136762, WO2008/119082 and WO 2010/062480, each of which is expressly incorporated by reference herein. In certain embodiments, the fatty alcohol biosynthetic polypeptide has aldehyde reductase or alcohol dehydrogenase (EC 1.1.1.1) activity.

[0098] In another approach, recombinant host cells have been engineered to produce fatty alcohols by expressing fatty alcohol-forming acyl-CoA reductases or fatty acyl reductases (FARs), which convert fatty acylthioester substrates (e.g., acyl-CoA fatty acid or fatty acyl-ACP) into fatty alcohols. In some embodiments, the fatty alcohol is produced by expressing or overexpressing a polynucleotide that encodes a polypeptide that has fatty alcohol-forming acyl-CoA reductase (FAR) activity in a recombinant host cell. Examples of FAR polypeptides useful in this embodiment are described in PCT Publication No. WO2010/062480 which is expressly incorporated by reference herein. Fatty alcohol can be produced via an acyl-CoA dependent pathway using acyl intermediates - Fatty and fatty acyl-CoA ACP and an acyl-CoA independent path that uses fatty acyl-ACP intermediates, but not a fatty acyl-CoA intermediate. In particular embodiments, the enzyme encoded by the overexpressed gene is selected from a fatty acid synthase, an acyl-ACP thioesterase, a fatty acyl-CoA synthase, and an acetyl-CoA carboxylase. In some embodiments, the protein encoded by the overexpressed gene is endogenous to the host cell. In other embodiments, the protein encoded by the overexpressed gene is heterologous to the host cell. Fatty alcohols are also made in nature by enzymes capable of reducing various molecules of acyl-ACP or acyl-CoA into corresponding primary alcohols. See also Patent Publications US 20100105963 and US 20110206630 and Patent US 8097439, expressly incorporated herein by reference. Strategies to increase the production of fatty alcohols by recombinant host cells include increased flux through the fatty acid biosynthetic pathway by overexpression of native fatty acid biosynthetic genes and/or by expression of exogenous fatty acid biosynthetic genes from different organisms in the host. producer, so that fatty alcohol biosynthesis is increased.

ester production

[0099] As used herein, the term "fatty ester" may be used as a reference to an ester. A fatty ester, as referred to herein, can be any ester made from a fatty acid, for example, a fatty acid ester. In some embodiments, a fatty ester contains an A side and a B side. As used herein, an "A side" of an ester refers to the carbon chain attached to the carboxylated oxygen of the ester. As used herein, a "B-side" of an ester refers to the carbon chain comprising the parent carboxylate of the ester. In embodiments where the fatty ester is derived from the biosynthetic path of the fatty acid, the A side is contributed by an alcohol and the B side is contributed by a fatty acid. Any alcohol can be used to form the A side of fatty esters. For example, alcohol can be derived from the fatty acid biosynthetic pathway. Alternatively, alcohol can be produced via biosynthetic pathways that are not fatty acid. In addition, alcohol can be provided exogenously. For example, alcohol may be provided in the fermentation broth in cases where the fatty ester is produced by an organism. Alternatively, a carboxylic acid, such as a fatty acid or an acetic acid, may be provided exogenously in cases where the fatty ester is produced by an organism which may also produce alcohol. The carbon chain comprising the A-side or B-side can be of any length. In one embodiment, the A side of the ester is at least about 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, or 18 carbons in length. When the fatty ester is a fatty acid methyl ester, the A side of the ester is 1 carbon long. When the fatty ester is an ethyl fatty acid ester, the A side of the ester is 2 carbons long. The B-side of the ester can be at least about 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, or 26 carbons in length. The A-side and/or the B-side may be straight-chain or branched. Branched chains can have one or more branch points. Additionally, branched chains may include cyclic branches. Furthermore, side A and/or side B can be saturated or unsaturated. If unsaturated, side A and/or side B may have one or more points of unsaturation. In one embodiment, the fatty ester is biosynthetically produced. In this embodiment, the fatty acid is first activated. Non-limiting examples of "activated" fatty acids are acyl-CoA, acyl ACP and acylphosphate. Acyl-CoA can be a direct product of fatty acid biosynthesis or degradation. Additionally, acyl-CoA can be synthesized from a free fatty acid, a CoA and an adenosine nucleotide triphosphate (ATP). An example of an enzyme that produces acyl-CoA is acyl-CoA synthase. In some embodiments, the recombinant host cell comprises a polynucleotide that encodes a polypeptide, for example, an enzyme that has ester synthase activity, (an ester synthase polypeptide or an ester synthase).

[00100] A fatty ester is produced by a reaction catalyzed by ester synthase polypeptide expressed or overexpressed in the recombinant host cell. In some embodiments, a composition comprising fatty esters is produced by growing the recombinant cell in culture in the presence of a carbon source under conditions effective to express an ester synthase. In some embodiments, the fatty ester composition is recovered from the cell culture. Ester synthase polypeptides include, for example, an ester synthase polypeptide classified as EC 2.3.1.75, or any other polypeptide that catalyzes the conversion of an acylthioester to a fatty ester including, without limitation, a thioesterase, an ester synthase, a acyl-CoA:alcohol transacylase, an acyltransferase, or a fatty acyl-CoA:fatty alcohol acyltransferase. For example, the polynucleotide may encode cera/dgat, a bifunctional ester synthase/acyl-CoA:diacylglycerol acyltransferase from Simmondsia chinensis, the ADP strain of Acinetobacter sp., Alcanivorax borkumensis, Pseudomonas aeruginosa, Fundibacter jadensis, Arabidopsis thaliana or Alkaligenes eutrophus . In a particular embodiment, the ester synthase polypeptide is a diacylglycerol O-acyltransferase from Acinetobacter sp. (wax-dgaT; UniProtKB Q8GGG1, GenBank AA017391) or Simmondsia chinensis cera synthase (UniProtKB Q9XGY6, GenBank AAD38041. In another embodiment, the ester synthase polypeptide is for example ES9 (a wax ester synthase from Marinobacter hydrocarbonoclasticus DSM 8798, UniProtKB A3RE51 ( SEQ ID NO: 6); ES8 from Marinobacter hydrocarbonoclasticus DSM8789 (GenBank Accession No. ABO21021; SEQ ID NO:7); GenBank ABO21021, encoded by the ws2 gene; or ES376 (another ester synthase wax derived from Marinobacter hydrocarbonoclasticus DSM 8798, UniProtKB A3RE50 , GenBank ABO21020, encoded by the wsl gene. In a particular embodiment, the polynucleotide encoding the ester synthase polypeptide is overexpressed in the recombinant host cell. In some embodiments, a fatty acid ester is produced by a recombinant host cell engineered to express three fatty acid biosynthetic enzymes: a thioesterase enzyme, an acyl-CoA synthetase (fadD) enzyme, and an esterase enzyme. r synthase (eg, the three enzyme system; see Figure 5). In other embodiments, a fatty acid ester is produced by a recombinant host cell engineered to express a biosynthetic fatty acid enzyme, an ester synthase enzyme (eg, an enzyme system; see Figure 5). Non-limiting examples of ester synthase polypeptides and polynucleotides encoding them suitable for use in these embodiments include those described in PCT Publications No. WO2007/136762 and WO2008/119082 and WO/2011/038134 (three enzyme system) and WO/2011/038132 (one enzyme system), each of which is expressly incorporated by reference herein. The recombinant host cell can produce a fatty ester, such as a fatty acid methyl ester, an ethyl fatty acid ester, or a wax ester in the extracellular environment of the host cell.

Production of Hydrocarbons

[00101] This aspect of the disclosure is based at least in part on the finding that altering the expression level of a fatty aldehyde biosynthetic polypeptide, for example, an acyl-ACP reductase polypeptide (EC 6.4.1.2) and a biosynthetic polypeptide of hydrocarbon, for example a decarbonylase in a recombinant host cell, facilitates enhanced production of hydrocarbons by the recombinant host cell. In one embodiment, the recombinant host cell produces a hydrocarbon, such as an alkane or alkene (e.g., a terminal olefin or an internal olefin) or a ketone. In some embodiments, a fatty aldehyde produced by a recombinant host cell is converted by decarbonylation, which removes a carbon atom to form a hydrocarbon. In other embodiments, a fatty acid produced by a recombinant host cell is converted by decarboxylation, which removes a carbon atom to form a terminal olefin. In some embodiments, an acyl-ACP intermediate is converted by decarboxylation, which removes a carbon atom to form an internal olefin or a ketone (see Figure 6). In some embodiments, the recombinant host cell comprises a polynucleotide that encodes a polypeptide (an enzyme) that has hydrocarbon biosynthetic activity (a hydrocarbon biosynthetic polypeptide or a hydrocarbon biosynthetic enzyme), and the hydrocarbon is produced by expression or overexpression of the biosynthetic enzyme. of hydrocarbon in a recombinant host cell. A cyanobacterial alkane biosynthetic pathway consisting of an acyl-acyl reductase (AAR) carrier protein and an aldehyde decarbonylase (ADC), which together convert fatty acid metabolism intermediates to alkanes and alkenes, has been used to engineer the recombinant host cells for the production of hydrocarbons (Figure 6). The second of two reactions in the pathway by which saturated acyl-ACPs are converted to alkanes in cyanobacteria comprises the cleavage of the C1-C2 bond of a fatty aldehyde intermediate by the enzyme aldehyde decarbonylase (ADC), a ferritin-like protein with a binuclear metallic cofactor of unknown composition. In some embodiments, the hydrocarbon is produced by expressing or overexpressing in the recombinant host cell a polynucleotide that encodes a polypeptide that has hydrocarbon biosynthetic activity, such as an aldehyde decarbonylase (ADC) activity (eg, EC 4.1.99.5 ). Exemplary polynucleotides encoding an aldehyde decarbonylase useful in this embodiment include, but are not limited to, those described in PCT Publications Nos. WO2008/119082 and WO2009/140695 which are expressly incorporated by reference herein and those sequences presented in Table 2 below. In some embodiments the recombinant host cell further comprises a polynucleotide encoding a fatty aldehyde biosynthesizing polypeptide. In some embodiments the recombinant host cell further comprises a polynucleotide encoding an acyl-ACP reductase. See, for example, Table 2 below. Table 2: Exemplary Hydrocarbon Biosynthetic Polynucleotides and Polypeptides

[00102] In some embodiments, a composition is produced by growing the recombinant cell in the presence of a carbon source under conditions effective to express Acyl-CoA reductase and decarbonylase polynucleotides. In some embodiments, the hydrocarbon composition comprises saturated and unsaturated hydrocarbons. However, a hydrocarbon composition may comprise other fatty acid derivatives. Typically, the hydrocarbon composition is recovered from the extracellular environment of the recombinant host cell, i.e., from the cell culture medium. As used herein, an alkane refers to hydrocarbons or saturated compounds consisting solely of carbon (C) and hydrogen (H), these atoms being held together by single bonds (ie, they are saturated compounds). Olefins and alkenes refer to hydrocarbons that contain at least one carbon-to-carbon double bond (i.e., are unsaturated compounds). Terminal olefins, α-olefins, terminal alkenes and l-alkenes refer to the same compounds, with a reference to α-olefins or alkenes with a chemical formula CxH2x, which distinguishes them from other olefins with a similar molecular formula by the linearity of the hydrocarbon chain and the position of the double bond in the alpha or primary position. In some embodiments, a terminal olefin is produced by expressing or overexpressing in the recombinant host cell a polynucleotide encoding a hydrocarbon biosynthetic polypeptide, such as a polypeptide having decarboxylase activity as described, for example, in PCT Publication No. WO2009/ 085278 which is expressly incorporated by reference herein. In some embodiments the recombinant host cell further comprises a polynucleotide encoding a thioesterase. In other embodiments, a ketone is produced by expressing or overexpressing in the recombinant host cell a polynucleotide encoding a hydrocarbon biosynthetic polypeptide, such as a polypeptide having OleA activity as described, for example, in PCT Publication No WO2008/147781 , which is expressly incorporated by reference herein. In related embodiments, an internal olefin is produced by expressing or overexpressing in the recombinant host cell a polynucleotide that encodes a hydrocarbon biosynthetic polypeptide, such as a polypeptide that has OleCD activity or OleBCD, together with a polypeptide having OleA activity as described, for example, in PCT Publication No. WO2008/147781, expressly incorporated by reference herein.

Recombinant Host Cells and Cell Cultures

[00103] Strategies to increase production of fatty acid derivatives by recombinant host cells include increased flux through the fatty acid biosynthetic pathway by overexpression of native fatty acid biosynthetic genes and by expression of exogenous fatty acid biosynthetic genes from different organisms in the producing host. As used herein, a recombinant or engineered host cell host cell refers to a host cell whose genetic makeup has been altered relative to the corresponding wild-type host cell, for example, by deliberate introduction of new genetic elements and /or deliberate modification of genetic elements naturally present in the host cell. The progeny of such recombinant host cells also contain such new and/or modified genetic elements. In any of the aspects of the disclosure described herein, the host cell may be selected from the group consisting of a plant cell, insect cell, fungal cell (e.g., from a filamentous fungus such as Candida sp., or a germinal yeast, such as Saccharomyces sp.), an algal cell and a bacterial cell. In a preferred embodiment, the recombinant host cells are recombinant microorganisms. Examples of host cells that are microorganisms include, but are not limited to, cells of the genera Escherichia, Bacillus, Lactobacillus, Zymomonas, Rhodococcus, Pseudomonas, Aspergillus, Trichoderma, Neurospora, Fusarium, Humicola, Rhizomucor, Kluyveromyces, Pichia, Mucor, Myceliophthora, Penicillium , Phanerochaete, Pleurotus, Trametes, Chrysosporium, Saccharomyces, Stenotrophamonas, Schizosaccharomyces, Yarrowia or Streptomyces. In some embodiments, the host cell is a gram-positive bacterial cell. In other embodiments, the host cell is a gram-negative bacterial cell. In some embodiments, the host cell is an E. coli cell. In other embodiments, the host cell is a Bacillus lentus cell, a Bacillus brevis cell, a Bacillus stearothermophilus cell, a Bacillus lichenoformis cell, a Bacillus alkalophilus cell, a Bacillus coagulans cell, a Bacillus circulans cell, a Bacillus pumilis cell, a Bacillus thuringiensis cell, a Bacillus clausii cell, a Bacillus megaterium cell, a Bacillus subtilis cell or a Bacillus amyloliquefaciens cell. In other embodiments, the host cell is a Trichoderma koningii cell, a Trichoderma viride cell, a Trichoderma reesei cell, a Trichoderma longibrachiatum cell, an Aspergillus awamori cell, an Aspergillus fumigates cell, an Aspergillus foetidus cell, an Aspergillus nidulans cell, an Aspergillus niger cell, an Aspergillus oryzae cell, a Humicola insolens cell, a Humicola lamiginose cell, a Rhodococcus opacus cell, a Rhizomucor michei cell, or a Mucor michei cell. In still other embodiments, the host cell is a Streptomyces lividans cell or a Streptomyces murinus cell. In still other embodiments, the host cell is an Actinomycetes cell. In some embodiments, the host cell is a Saccharomyces cerevisiae cell. In other embodiments, the host cell is a cell of a eukaryotic plant, algae, cyanobacterium, green sulfur bacteria, green non-sulfur bacteria, purple sulfur bacteria, purple non-sulfur bacteria, extremophiles, yeast, fungus, an organism engineered therefrom or a synthetic organism. In some embodiments, the host cell is photodependent or carbon-fixing. In some embodiments, the host cell has autotrophic activity. In some embodiments, the host cell has photoautotrophic activity, such as in the presence of light. In some embodiments, the host cell is heterotrophic or mixotrophic in the absence of light. In certain embodiments, the host cell is a cell of Arabidopsis thaliana, Panicum virgatum, Miscanthus giganteus, Zea mays, Botryococcuse braunii, Chlamydomonas reinhardtii, Dunaliela salina, Synechococcus Sp. PCC 7002, Synechococcus Sp. PCC 7942, Synechocystis Sp. PCC 6803, Thermosynechococcus elongates BP-1, Chlorobium tepidum, Chlorojlexus auranticus, Chromatiumm vinosum, Rhodospirillum rubrum, Rhodobacter capsulatus, Rhodopseudomonas palusris, Clostridium ljungdahlii, Clostridiuthermocellum, Penicillium chrysogenum, Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pseudomonas fluorescens, or Zymomonas mobilis.

Production of Fatty Acid Derivative Compositions by Recombinant Host Cells

[00104] A wide variety of fatty acid derivatives can be produced by recombinant host cells that comprise strain enhancements as described herein including, but not limited to, fatty acids, acyl-CoA, fatty aldehydes, long and short chain alcohols , hydrocarbons (e.g. alkanes, alkenes or olefins, such as terminal or internal olefins), fatty alcohols, esters (e.g. wax esters, fatty acid esters (e.g. methyl or ethyl esters)) and ketones. In some embodiments of the present disclosure, the higher titration of fatty acid derivatives in a particular composition is a higher titration of a particular type of fatty acid derivative (e.g., fatty alcohols, fatty acid esters or hydrocarbons) produced by a culture of recombinant host cell against the titration of the same fatty acid derivatives produced by a control culture of a corresponding wild-type host cell. In such cases, the composition derived from fatty acids may comprise, for example, a mixture of fatty alcohols with a variety of chain lengths and saturation or branching characteristics. In other embodiments of the present disclosure, the higher titration of fatty acid derivatives in a particular composition is a higher titration of a combination of different fatty acid derivatives (e.g., fatty aldehydes and alcohols, or fatty acids and esters) against the titration of the same fatty acid derivative produced by a control culture of a corresponding wild-type host cell.

Engineering Host Cells

[00105] In some embodiments, a sequence of polynucleotides (or genes) is provided to the host cell by means of a recombinant vector, which comprises a promoter unit operably to the sequence of polynucleotides. In certain embodiments, the promoter is a developmentally regulated, organelle-specific, tissue-specific, inducible, constitutive, or cell-specific promoter. In some embodiments, the recombinant vector includes at least one sequence which includes, but is not limited to (a) an expression control sequence operably coupled to the polynucleotide sequence; (b) a selection marker operably coupled to the polynucleotide sequence; (c) a marker sequence operably coupled to the polynucleotide sequence; (d) a purifying chemical moiety operably coupled to the polynucleotide sequence; (e) a secretion sequence operably coupled to the polynucleotide sequence; and (f) a targeting sequence operably coupled to the polynucleotide sequence. Expression vectors described herein include a polynucleotide sequence described herein in a form suitable for expression of the polynucleotide sequence in a host cell. It will be appreciated by persons skilled in the art that the design of the expression vector may depend on such factors as the choice of host cell to be transformed, the desired level of polypeptide expression, etc. The expression vectors described herein can be introduced into host cells to produce polypeptides, including fusion polypeptides, encoded by the polynucleotide sequences as described herein. Expression of genes encoding polypeptides in prokaryotes, eg E. coli, is most commonly performed with vectors that contain constitutive or inducible promoters that direct the expression of both fusion and other polypeptides. Fusion vectors add an amount of amino acids to a polypeptide encoded therein, usually to an amino- or carboxy-terminus of the recombinant polypeptide. Such fusion vectors typically serve one or more of the following three purposes (1) to increase expression of the recombinant polypeptide; (2) increasing the solubility of the recombinant polypeptide; and (3) aiding in the purification of the recombinant polypeptide by acting as a linker in affinity purification. Commonly, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion chemical moiety with the recombinant polypeptide. This makes it possible to separate the recombinant polypeptide from the fusion chemical moiety after purification of the fusion polypeptide. Examples of such enzymes and their cognate recognition sequences include Factor Xa, thrombin and enterokinase. Exemplary fusion expression vectors include pGEX (Pharmacia Biotech, Inc., Piscataway, NJ; Smith et al., Gene, 67: pages 31 to 40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRITS ( Pharmacia Biotech, Inc., Piscataway, NJ), which fuse glutathione S-transferase (GST), maltose binding protein E, or protein A, respectively, to the target recombinant polypeptide. Examples of inducible and non-fusion E. coli expression vectors include pTrc (Amann et al, Gene (1988) 69: pages 301 to 315) and pET 11d (Studier et al, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) pages 60 to 89). Targeted gene expression of the pTrc vector depends on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Targeted gene expression of the pET 11d vector depends on the transcription of a T7 gn10-lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7 gn1). This viral polymerase is provided by the host strains BL21(DE3) or HMS174(DE3) from a resident A prophage that carries a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter. Expression systems suitable for both prokaryotic and eukaryotic cells are well known in the art; see, for example, Sambrook et al, "Molecular Cloning: A Laboratory Manual", second edition, Cold Spring Harbor Laboratory, (1989). Examples of inducible, non-fusion vectors of E. coli expression include pTrc (Amann et al, Gene, 69: pages 301 to 315 (1988)) and PET 11d (Studier et al, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA, pages 60 to 89 (1990)). In certain embodiments, a polynucleotide sequence of the disclosure is operably linked to a promoter derived from bacteriophage T5. In one embodiment, the host cell is a yeast cell. In this embodiment, the expression vector is a yeast expression vector. Vectors can be introduced into prokaryotic or eukaryotic cells via various art-recognized procedures for introducing foreign nucleic acid (e.g., DNA) into a host cell. Suitable methods for transforming or transfecting host cells can be found, for example, in Sambrook et al. (supra). For the stable transformation of bacterial cells it is known that, depending on the expression vector and transformation procedure used, only a small fraction of the cells will take up and replicate the expression vector. In order to identify and select these transformants, a gene encoding a selectable marker (eg, antibiotic resistance) can be introduced into host cells along with the relevant gene. Selectable markers include those that confer resistance to drugs such as, but not limited to, ampicillin, kanamycin, chloramphenicol, or tetracycline. Nucleic acids encoding a selectable marker may be introduced into a host cell in the same vector which encodes a polypeptide described herein, or may be introduced in a separate vector. Cells stably transformed with the introduced nucleic acid can be identified by growth in the presence of an appropriate screening drug.

host cells

[00106] As used herein, a recombinant or engineered host cell is a cell used to produce a fatty acid derivative composition as further described herein. A host cell is said to be an engineered host cell or a recombinant host cell if the expression of one or more polynucleotides or polypeptides in the host cell is altered or modified as compared to expression in a corresponding wild-type host cell (eg. example, control cell) under the same conditions. In any of the aspects of the disclosure described herein, the host cell may be selected from the group consisting of a eukaryotic plant, alga, cyanobacteria, green sulfur bacteria, green non-sulfur bacteria, purple sulfur bacteria, purple non-sulfur bacteria , extremophile, yeast, fungus, engineered organisms thereof, or a synthetic organism. In some embodiments, the host cell is photodependent or carbon fixed. In some embodiments, the host cell has autotrophic activity. Various host cells can be used to produce fatty acid derivatives as described herein.

Mutants or Variants

[00107] In some embodiments, the polypeptide is a mutant or a variant of any of the polypeptides described herein. The terms mutant and variant as used herein refer to a polypeptide that has an amino acid sequence that differs from that of a wild-type polypeptide by at least one amino acid. For example, the mutant may comprise one or more of the following conservative amino acid substitutions: substitution of an aliphatic amino acid, such as alanine, valine, leucine and isoleucine, with another aliphatic amino acid; replacement of a serine with a threonine; replacement of a threonine with a serine; replacing an acidic residue, such as aspartic acid and glutamic acid, with another acidic residue; replacing a residue bearing an amide group, such as asparagine and glutamine, with another residue bearing an amide group; exchanging a basic residue, such as lysine and arginine, with another basic residue; and replacing an aromatic residue, such as phenylalanine and tyrosine, with another aromatic residue. In some embodiments, the mutant polypeptide has approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more amino acid substitutions, additions, insertions or deletions. Preferred fragments or mutants of a polypeptide retain part or all of the biological function (eg, enzymatic activity) of the corresponding wild-type polypeptide. In some embodiments, the fragment or mutant retains at least 75%, at least 80%, at least 90%, at least 95%, or at least 98% or more of the biological function of the corresponding wild-type polypeptide. In other embodiments, the fragment or mutant retains approximately 100% of the biological function of the corresponding wild-type polypeptide. Guidelines for determining which amino acid residues can be substituted, inserted, or deleted without affecting biological activity can be found using computer programs well known in the art, for example, LASERGENETM software (DNASTAR, Inc., Madison, WI). In still other embodiments, a fragment or mutant exhibits increased biological function compared to a corresponding wild-type polypeptide. For example, a fragment or mutant can exhibit an improvement in enzyme activity of at least 10%, at least 25%, at least 50%, at least 75%, or at least 90% compared to the corresponding wild-type polypeptide. In other embodiments, the fragment or mutant exhibits at least 100% (e.g., at least 200%, or at least 500%) improvement in enzyme activity compared to the corresponding wild-type polypeptide. It is understood that the polypeptides described herein may have additional conservative or non-essential amino acid substitutions which have no substantial effect on the function of the polypeptide. Whether or not a particular substitution will be tolerated (ie, whether or not it will adversely affect biological function, such as carboxylic acid reductase activity) can be determined as described in Bowie et al. (Science, 247: pages 1306 to 1310 (1990)). A conservative amino acid substitution is one in which the amino acid residue is replaced by an amino acid residue that has a similar side chain. Families of amino acid residues that have similar side chains have been defined in the art. These families include amino acids with basic side chains (eg, lysine, arginine, histidine), acidic side chains (eg, aspartic acid, glutamic acid), uncharged polar side chains (eg, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g. threonine, valine, isoleucine) and side chains aromatics (eg tyrosine, phenylalanine, tryptophan, histidine).

[00108] Variants can be naturally occurring or created in vitro. In particular, such variants can be created using genetic engineering procedures, such as site-directed mutagenesis, chemical random mutagenesis, Exonuclease III deletion procedures, or standard cloning procedures. Alternatively, such variants, fragments, analogs, or derivatives can be created using synthetic or chemical modification procedures. Methods for producing variants are well known in the art. They include procedures in which nucleic acid sequences obtained from natural isolates are modified to generate nucleic acids encoding polypeptides that have characteristics that enhance their value in industrial or laboratory applications. In such procedures, a wide variety of variant sequences that have one or more nucleotide differences from the sequence obtained from the natural isolate are generated and characterized. Typically, these nucleotide differences result in amino acid changes with respect to polypeptides encoded by nucleic acids from natural isolates. For example, variants can be prepared using random mutagenesis and site-directed mutagenesis. Random and site-directed mutagenesis are described, for example, in Arnold, Curr. opinion Biotech., 4: pages 450 to 455 (1993). Random mutagenesis can be achieved using error-prone PCR (see, for example, Leung et al., Technique, 1: pages 11 to 15 (1989); and Caldwell et al., PCR Methods Applic, 2: pages 28 to 33 (1992)). In error-prone PCR, PCR is performed under conditions where the copy fidelity of DNA polymerase is low, so that a high rate of point mutations is obtained over the entire length of the PCR product. Briefly, in such procedures, the nucleic acids to be mutagenized (e.g. a polynucleotide sequence encoding a carboxylic reductase enzyme) are mixed with PCR primers, reaction buffer, MgCl2, MnCl2, Taq polymerase and an appropriate concentration of dNTPs. to achieve a high point mutation rate over the entire length of the PCR product. For example, the reaction can be carried out using 20 fmols of nucleic acid to be mutagenized, 30 pmoles of each PCR primer, a reaction buffer comprising 50 mM per kg, 10 mM Tris HCl (pH 8.3) , 1% elatin, 7 mM MgCl 2 , 0.5 mM MgCl 2 , 5 units Taq polymerase, 0.2 mM dGTP, 0.2 mM dATP, 1 mM dCTP and 1 mM dTTP. PCR can be carried out for 30 cycles of 94 °C for 1 min, 45 °C for 1 min and 72 °C for 1 min. However, it will be appreciated that these parameters can be varied as appropriate. The mutated nucleic acids are then cloned into an appropriate vector and the activities of the polypeptides encoded by the mutated nucleic acids are evaluated. Site-directed mutagenesis can be achieved using oligonucleotide-directed mutagenesis to generate site-specific mutations in any relevant cloned DNA. Oligonucleotide mutagenesis is described, for example, in Reidhaar-Olson et al., Science, 241: pages 53 to 57 (1988). Briefly, in such procedures, a plurality of double-stranded oligonucleotides that carry one or more mutations to be introduced into the cloned DNA are synthesized and inserted into the cloned DNA to be mutagenized (e.g., a polynucleotide sequence encoding a CAR polypeptide). Clones that contain the mutated DNA are recovered and the activities of the polypeptides they encode are determined. Another method for generating variants is assembly PCR. Assembly PCR involves assembling a PCR product from a mixture of small DNA fragments. A wide variety of different PCR reactions take place in parallel in the same flask, with the products of one reaction starting the products of another reaction. Assembly PCR is described, for example, in US Patent No. 5,965,408. Yet another method of generating variants is sexual mutagenesis PCR. In sexual mutagenesis PCR, forced homologous recombination occurs between DNA molecules of different but highly related DNA sequences in vitro as a result of random fragmentation of the DNA molecule based on sequence homology. This is followed by fixing the crossover by primer extension in a PCR reaction. Sexual mutagenesis PCR is described, for example, in Stemmer, Proc. natl. academy Sci., USA, 91: pages 10747 to 10751 (1994). Variants can also be created by in vivo mutagenesis. In some embodiments, random mutations in a nucleic acid sequence are generated by propagating the sequence in a bacterial strain, such as an E. coli strain, that carries the mutations in one or more of the DNA repair pathways. Such "mutation-causing" strains have a higher rate of random mutation than a wild-type strain. Propagating a DNA sequence (eg, a polynucleotide sequence encoding a CAR polypeptide) in one of these strains will eventually generate random mutations within the DNA. Mutation-causing strains suitable for use for in vivo mutagenesis are described, for example, in International Patent Application Publication No. WO1991/016427. Variants can also be generated using cassette mutagenesis. In cassette mutagenesis, a small region of a double-stranded DNA molecule is replaced with a synthetic oligonucleotide "cassette" that differs from the native sequence. The oligonucleotide commonly contains a completely and/or partially random altered native sequence. Recursive set mutagenesis can also be used to generate variants. Recursive ensemble mutagenesis is an algorithm for engineering a protein (ie, protein mutagenesis) designed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive times of combinatorial cassette mutagenesis. Recursive ensemble mutagenesis is described, for example, in Arkin et al, Proc. natl. academy Sci., USA, 89: pages 7811 to 7815 (1992). In some embodiments, variants are created using exponential set mutagenesis. Exponential set mutagenesis is a process to generate combinatorial libraries with a high percentage of unique and functional mutants, where small groups of residues are randomly altered in parallel to identify, at each altered position, amino acids that lead to functional proteins. Exponential set mutagenesis is described, for example, in Delegrave et al., Biotech. Res, 11: pages 1548 to 1552 (1993). In some embodiments, variants are created using scrambling procedures, whereby some portions of a plurality of nucleic acids encoding distinct polypeptides are fused together to create chimeric nucleic acid sequences encoding chimeric polypeptides as described, for example, in US Patents 5,965,408 and 5,939,250. Insertional mutagenesis is the mutagenesis of DNA by the insertion of one or more bases. Insertional mutations may occur naturally, mediated by viruses or transposon, or may be artificially created for laboratory research purposes, for example, by transposon mutagenesis. When exogenous DNA is integrated into a host's DNA, the severity of any consequential mutation depends entirely on the location in the host's genome into which the DNA is inserted. For example, significant effects may be evident if a transposon is inserted in the middle of an essential gene, in a promoter region, or within a repressor or enhancer region. A transposon mutagenesis and high-throughput screening were performed to find beneficial mutations that increase the titration or yield of fatty acid derivatives or derivatives.

Fermentation by Recombinant Host Cells in Culture and Cell Cultures

[00109] As used herein, the term "fermentation" broadly refers to the conversion of organic materials into target substances by host cells, for example, the conversion of a carbon source by recombinant host cells into fatty acids or derivatives thereof by propagating a culture of the recombinant host cells in a medium comprising the carbon source. As used herein, the term "production enabling conditions" means any conditions that allow a host cell to produce a desired product, such as a fatty acid or fatty acid derivative. Similarly, the term "conditions under which the polynucleotide sequence of a vector is expressed" means any conditions that allow a host cell to synthesize a polypeptide. Suitable conditions include, for example, fermentation conditions. Fermentation conditions can comprise many parameters including, but not limited to, temperature ranges, aeration levels, feed rates and medium composition. Each of these conditions, individually and in combination, allows for the development of the host cell. Fermentation can be aerobic, anaerobic or variations thereof (such as microaerobic). An exemplary culture medium includes broths or gels. Generally, the medium includes a carbon source that can be metabolized by a host cell directly. Additionally, enzymes can be used in the medium to facilitate mobilization (eg, depolymerization of starch or cellulose to fermentable sugars) and subsequent metabolism of the carbon source. For small-scale production, engineered host cells can be grown in batches of, for example, approximately 100 ml, 500 ml, 1 l, 2 l, 5 l, or 10 l; fermented; and induced to express a desired polynucleotide sequence, such as a polynucleotide sequence encoding a CAR polypeptide. For large-scale production, engineered host cells can be developed in batches of about 10L, 100L, 1000L, 10,000L, 100,000L and 1,000,000L or more; fermented; and induced to express a desired polynucleotide sequence. Alternatively, large-scale fed-batch fermentation can be performed. The fatty acid-derived compositions described herein are found in the extracellular environment of the recombinant host cell culture and can be readily isolated from the culture medium. A fatty acid derivative can be secreted by the recombinant host cell, transported into the extracellular environment, or passively transferred into the extracellular environment of the recombinant host cell culture. The fatty acid derivative is isolated from a recombinant host cell culture using routine methods known in the art.

Products Derived from Recombinant Host Cells

[00110] As used herein, "modern carbon fraction" or fM has the same meaning as defined by the National Institute of Standardization and Technology (NIST) Standards Reference Materials (SRMs4990B and 4990C, known as standard oxalic acids HOxI and HOxII, respectively. The fundamental definition refers to 0.95 times the 14C/12C isotope ratio of HOxI (referring to the year 1950). This is roughly equivalent to pre-industrial revolution wood corrected for decay. current existing biosphere (plant material), fM is approximately 1.1. Bioproducts (e.g., fatty acid derivatives produced in accordance with the present disclosure) which comprise biologically produced organic compounds, and in particular, acid derivatives produced using the fatty acid biosynthetic pathway in this document, were not produced from renewable sources and, therefore, are new compositions of matter. These new bioproducts can be distinguished from organic compounds derived from petrochemical carbon on the basis of double carbon isotope signature or 14C dating. Additionally, the specific carbon source of the biological source (e.g., glucose vs. glycerol) can be determined by double carbon isotope signature (see, for example, US Patent No. 7,169,588, which is incorporated herein by way of title). of reference). The ability to distinguish bioproducts from petroleum-based organic compounds is beneficial in tracing these materials in commerce. For example, organic compounds or chemicals that comprise both petroleum-based and bio-based carbon isotope profiles can be distinguished from organic compounds and chemicals made only from petroleum-based material. Therefore, the bioproducts in this document may be tracked or tracked in trade based on their unique carbon isotope profile. Bioproducts can be distinguished from petroleum-based organic compounds by comparing the stable carbon isotope ratio (13C/12C) in each sample. The 13C/12C ratio in a given bioproduct is a consequence of the 13C/12C ratio in atmospheric carbon dioxide at the time the carbon dioxide is fixed. It also reflects the metabolic trajectory. Regional variations also occur. Among petroleum, C3 plants (the broadleaved ones), C4 plants (the grasses) and marine carbonates all show significant differences in the 13C/12C values and in the corresponding δ13C value. Furthermore, the lipid matter of C3 and C4 plants is analyzed differently from materials derived from the carbohydrate components of the same plants, as a consequence of the metabolic pathway. Within measurement accuracy, 13C shows large variations due to isotope fractionation effects, of which the most significant for bioproducts is the photosynthetic mechanism. The main cause of differences in carbon isotope ratio in plants is strongly associated with differences in the pathway of photosynthetic carbon metabolism in plants, particularly the reaction that occurs during primary carboxylation (ie, initial fixation of atmospheric CO2). Two major classes of vegetation are those that incorporate the "C3" (or Calvin-Benson) photosynthetic cycle and those that incorporate the "C4" (or Hatch-Slack) photosynthetic cycle. In C3 plants, the primary CO2 fixation or carboxylation reaction involves the enzyme ribulose-1,5-diphosphate carboxylase and the first stable product is a 3-carbon compound. C3 plants, such as hardwoods and conifers, are dominant in temperate climate zones. In C4 plants, an additional carboxylation reaction that involves another enzyme, phosphoenol-pyruvate carboxylase, is the primary carboxylation reaction. The first stable carbon compound is a 4-carbon acid that is subsequently decarboxylated. The CO2 thus released is reset by the C3 cycle. Examples of C4 plants are tropical grasses, corn and sugar cane. Both C4 and C3 plants exhibit a range of 13C/12C isotopic ratios, but typical values are approximately -7 to about -13 per thousand for C4 plants and approximately -19 to about -27 per thousand for C3 plants (see, for example, Stuiver et al, Radiocarbon 19:355 (1977)). Carbon and coal generally fall into this latter range. The 13C measurement scale was originally defined by a zero set for Pee Dee Belemnite Limestone (PDB), where values are given in deviations from that material in parts per thousand. The "δ13C" values are expressed in parts per thousand (per thousand), abbreviated as, &,, and are calculated as follows:

[00111] As the PDB reference material (RM) was exhausted, a number of alternative RMs were developed in cooperation with IAEA, USGS, NIST and other selected international isotope laboratories. Notations for the deviations per thousand of the PDB is δ13C. Measurements are made in CO2 by high precision stable ratio mass spectrometry (IRMS) on molecular ions ions of masses 44, 45 and 46. The compositions described herein include bioproducts produced by any of the methods described herein. including, for example, aldehyde and fatty alcohol products. Specifically, the byproduct may have a δ13C of about -28 or greater, approximately -27 or greater, -20 or greater, -18 or greater, -15 or greater, -13 or greater, -10 or greater, or -8 or larger. For example, the byproduct may have a δ13C of about -30 to about -15, from about -27 to about -19, from about -25 to about -21, from about -15 to about -5, from about -13 to about -7 or from about -13 to about -10. In other cases, the byproduct may have a δ13C of about -10, -11, -12, or -12.3. Bioproducts produced in accordance with the disclosure herein can also be distinguished from petroleum-based organic compounds by comparing the amount of 14C in each compound. Due to the fact that 14C has a nuclear half-life of 5730 years, petroleum-based fuels that contain "older" carbon can be distinguished from bioproducts that contain "newer" carbon (see, for example, Currie, "Source Apportionment of Atmospheric Particles", Characterization of Environmental Particles, J. Buffle and HP van Leeuwen, Eds., 1 of Vol. I of the IUPAC Environmental Analytical Chemistry Series (Lewis Publishers, Inc.) pages 3 to 74, (1992)). The basic assumption of radiocarbon dating is that constant 14C concentration in the atmosphere leads to constant 14C in living organisms. However, due to atmospheric nuclear testing since 1950 and fossil fuel burning since 1850, 14C has acquired a second temporal geochemical characteristic. The concentration of atmospheric CO2, and therefore in the existing biosphere, approximately doubled at the peak of the amount of nuclear testing in the mid-1960s. It has since gradually returned to the basic cosmogenic (atmospheric) steady state isotopic rate (14C /12C) of about 1.2 x 10 to 12, with a relaxation "half-life" of 7 to 10 years. (This latter half-life is not to be taken literally; instead, one must use the atmospheric nuclear detailed admission/decay function to track the variation of atmospheric and biospheric 14C since the birth of the nuclear age.) It is this later biospheric temporal feature of 14C that maintains the possibility of recent annual biospheric carbon dating. 14C can be measured with accelerator mass spectrometry (AMS), the results being given in units of "fraction of modern carbon" (fM). The fM is defined by Standardization Reference Materials (SRMs) 4990B and 4990C from the National Institute of Standardization and Technology (NIST). As used herein, "modern carbon fraction" or "fM" has the same meaning as defined by the National Institute of Standards and Technology (NIST) Standards Reference Materials, known as the HOxI and HOxII standards of oxalic acids, respectively. . The fundamental definition refers to 0.95 times the 14C/12C isotope ratio of HOxI (referring to the year 1950). This is roughly equivalent to pre-industrial revolution wood corrected for decay. For the current existing biosphere (plant material) the fM is approximately 1.1. The compositions described herein include byproducts that can have a 14C fM of at least about 1. For example, the byproduct of the disclosure can have a 14C fM of at least about 1.01, a 14C fM of about 1.01. from 1 to about 1.5, a14C fM from about 1.04 to about 1.18, or a14C fM from about 1.111 to about 1.124.

[00112] Another measurement of 14C is known as the percentage of modern carbon (pMC). For an archaeologist or geologist using 14C dates, the year 1950 is equal to "zero years old". This also represents 100 pMC. Bomb carbon in the atmosphere reached nearly double the normal level in 1963 at the peak of thermonuclear weaponry. This distribution in the atmosphere has been approximated since its emergence, showing values that are greater than 100 pMC for living plants and animals since the 1950s. It has gradually decreased over time, with today's value approaching at 107.5 pMC. This means that fresh biomass material, such as corn, would have a 14C signature close to 107.5 pMC. Petroleum-based compounds will have a pMC value of zero. The combination of present day fossil carbon will result in a dilution of the pMC content. Assuming that 107.5 pMC represents the 14C content of present day biomass materials and that 0 pMC represents the 14C content of petroleum-based products, the measured pMC value for a material will reflect the proportions of the two types. of components. For example, a 100% material derived from modern day soybeans would give a radiocarbon signature close to 107.5 pMC. If that material had been diluted 50% with petroleum-based products, it would give a radiocarbon signature of approximately 54 pMC. A biobased carbon content is derived by setting "100%" equal to 107.5 pMC and "0%" equaling 0 pMC. For example, a sample with a measurement of 99 pMC will give a biobased carbon content equivalent to 93%. This value is called the average biobased carbon result and assumes that all components within the analyzed material originated from either present day biological material or from petroleum based material. A byproduct comprising one or more fatty acid derivatives as described herein may have a pMC of at least about 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100 In other cases, a fatty acid derivative described herein may have a pMC between approximately 50 and approximately 100; approximately 60 and approximately 100; approximately 70 and approximately 100; approximately 80 and approximately 100; approximately 85 and approximately 100; approximately 87 and approximately 98; or about 90 and about 95. In still other cases, a fatty acid derivative described herein may have a pMC of about 90, 91, 92, 93, 94, or 94.2.

Screening of Fatty Acid-Derived Compositions Produced by Recombinant Host Cells

[00113] To determine whether conditions are sufficient to allow expression, a host cell can be cultured, for example, for approximately 4, 8, 12, 24, 36, or 48 hours. During and/or after growth in culture, samples can be obtained and analyzed to determine if conditions permit expression. For example, host cells in the sample or in the medium in which the host cells were grown can be tested for the presence of a desired product. When testing for the presence of a product, assays such as, but not limited to, TLC, HPLC, GC/FID, GC/MS, LC/MS, MS, can be used. Recombinant host cell cultures are screened at the 96-well plate level, 1 liter and 5 liter tank levels and in a 1000 liter pilot plant using a GC/FID assay for "total fatty species" .

Usefulness of Compositions Derived from Fatty Acids

[00114] A fatty acid is a carboxylic acid with a long aliphatic tail (chain), which is either saturated or unsaturated. Most naturally occurring fatty acids have a chain of an even number of carbon atoms, from 4 to 28. Fatty acids are normally derived from triglycerides. When they are not attached to other molecules, they are known as "free" fatty acids. Fatty acids are normally produced industrially by the hydrolysis of triglycerides with the removal of glycerol. Palms, soybeans, rapeseed, coconut oil and sunflower oil are currently the most common sources of fatty acids. Most fatty acids derived from such sources are used in human food products. Coconut oil and palm kernel oil mainly consist of carbon 12 and 14 fatty acids. These are particularly suitable for further processing for surfactants for washing and cleaning agents as well as cosmetics. Palm, soybeans, rapeseed and sunflower oil, as well as animal fats such as tallow, mainly contain long-chain fatty acids (e.g. C18, saturated and unsaturated) that are used as raw materials for applications polymer and lubricants. Ecological and toxicological studies suggest that fatty acid-derived products based on renewable resources have more favorable properties than petrochemical-based substances. Fatty aldehydes are used to make many special chemicals. For example, aldehydes are used to make polymers, resins (e.g. Bakelite), dyes, flavors, plasticizers, perfumes, pharmaceuticals, and other chemicals, some of which can be used as solvents, preservatives, or disinfectants. Additionally, certain natural and synthetic compounds, such as vitamins and hormones, are aldehydes, and many sugars contain aldehyde groups. Fatty aldehydes can be converted to fatty alcohols through chemical or enzymatic reduction. Fatty alcohols have many commercial uses. Annual worldwide sales of fatty alcohols and their derivatives exceed one billion dollars. Shorter chain fatty alcohols are used in the cosmetics and food industries as emulsifiers, emollients and thickeners. Due to their amphiphilic nature, fatty alcohols behave as non-ionic surfactants, which are useful in personal and household care products such as, for example, detergents. Additionally, fatty alcohols are used in pharmaceutical waxes, gums, resins, ointments and lotions, lubricating oil additives, textile finishing and antistatic agents, plasticizers, cosmetics, industrial solvents and grease solvents. The disclosure also provides a surfactant composition or a detergent composition comprising a fatty alcohol produced by any of the methods described herein. A person of ordinary skill in the art will appreciate that, depending on the purpose for which the surfactant or detergent composition is intended, different fatty alcohols can be produced and used. For example, when the fatty alcohols described herein are used as a raw material for the production of surfactants or detergents, a person of ordinary skill in the art will realize that the characteristics of the fatty alcohol raw material will affect the characteristics of the surfactant composition. or detergent produced. Therefore, the characteristics of the surfactant or detergent composition can be selected to produce particular fatty alcohols for use as a raw material. A fatty alcohol-based surfactant and/or detergent composition described herein may be blended with other surfactants and/or detergents known in the art. In some embodiments, the mixture can include at least about 10%, at least about 15%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, or a range limited by any two of the foregoing values, by weight of fatty alcohol. In other examples, a surfactant or detergent composition can be made including at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 40% about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or a range limited by any two of the foregoing values by weight of a fatty alcohol that includes a carbon chain having 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 carbons long. Such surfactant or detergent compositions may also include at least one additive, such as a microemulsion, a surfactant, or a detergent, from non-microbial sources such as vegetable oils or petroleum, which may be present in an amount of at least about 5%, at least at least about 10%, at least about 15%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or in a range limited by any two of the foregoing values, by weight of fatty alcohol . Esters have many commercial uses. For example, biodiesel, an alternative fuel, is composed of esters (eg, fatty acid methyl esters, fatty acid ethyl esters, etc.). Some low molecular weight esters are volatile and have a pleasant smell, which makes them useful as fragrances or flavoring agents. Additionally, esters are used as solvents for lacquers, paints and varnishes. Furthermore, some naturally occurring substances such as waxes, fats and oils are composed of esters. Esters are also used as softening agents in resins and plasticizers, flame retardants and additives in gasoline and oil. Additionally, esters can be used in the manufacture of polymers, films, textiles, dyes and pharmaceutical substances. Hydrocarbons have many commercial uses. For example, shorter chain alkanes are used as fuels. Longer chain alkanes (eg, having five to sixteen carbons) are used as transportation fuels (eg, gasoline, diesel, or jet fuel). Alkanes that have more than sixteen carbon atoms are important components of fuel oils and lubricating oils. Even longer alkanes, which are solid at room temperature, can be used, for example, as a paraffin wax. Additionally, longer chain alkanes can be cracked to produce commercially valuable shorter chain hydrocarbons. Like short chain alkanes, short chain alkenes are used in transport fuels. Longer chain alkenes are used in plastics, lubricants, and synthetic lubricants. Additionally, alkenes are used as a raw material to produce alcohols, esters, plasticizers, surfactants, tertiary amines, enhanced oil recovery agents, fatty acids, thiols, alkenylsuccinic anhydrides, epoxides, chlorinated alkanes, chlorinated alkenes, waxes, additives. of fuel and drag flow reducers. Ketones are used commercially as solvents. For example, acetone is often used as a solvent, but it is also a raw material for making polymers. Ketones are also used in lacquers, paints, explosives, perfumes and in textile processing. Additionally, ketones are used to produce alcohols, alkenes, alkanes, imines and enamines. Lubricants are typically composed of olefins, particularly polyolefins and alpha-olefins. Lubricants can be either refined from crude oil or manufactured using crude materials refined from crude oil. Obtaining these special chemicals from crude oil requires a significant financial investment, as well as a great deal of energy. This process is also inefficient due to the fact that long-chain hydrocarbons in crude oil are often cracked to produce smaller monomers. These monomers are then used as the raw material for manufacturing more complex specialty chemicals. The disclosure is further illustrated by the following examples. Examples are provided for illustrative purposes only. They should not be interpreted as limiting the scope or content of the disclosure in any way.

EXAMPLES EXAMPLE 1 Production Host Modifications - Attenuation of Acyl-CoA Dehydrogenase

[00115] This example describes the construction of a genetically modified host cell, where the expression of a fatty acid degrading enzyme is attenuated.

[00116] The fadE gene from Escherichia coli MG1655 (a K strain of E. coli) was deleted using the Lambda Red system (also known as Red Driven Integration) described by Datsenlco et al, Proc. natl. academy Sci. United States, 1997: pages 6640 to 6645 (2000), with the following modifications:

[00117] The following two primers were used to create the fadE deletion: Del-fadE-F 5'- AAAAACAGCAACAATGTGAGCTTTGTTGTAATTATATTGTAAACATATTGATTCCGGGG ATCCGTCGACC (SEQ ID NO: 9); and Del-fadE-R 5'- AAACGGAGCCTTTCGGCTCCGTTATTCATTTACGCGGCTTCAACTTTCCTGTAGGCTGG AGCTGCTTC (SEQ ID NO: 10)

[00118] Primers Del-fadE-F and Del-fadE-R were used to amplify the kanamycin resistance (KmR) cassette of plasmid pKD13 (described by Datsenko et al, supra) by PCR. The PCR product was then used to transform electrocompetent E. coli MG1655 cells containing pKD46 (described in Datsenko et al., supra) that had been previously induced with arabinose for 3 to 4 hours. Following a 3 hour growth in a super optimal broth with a catabolic suppression medium (SOC) at 37°C, cells were placed on Luria agar plates containing 50 μg/ml kanamycin. Resistant colonies were identified and isolated after an overnight incubation at 37 °C. The fadE gene mischaracterization was confirmed by PCR amplification using the fadE-L2 and fadE-Rl primers, which are designed to flank the E. coli fadE gene.

[00119] The fadE deletion confirmation primers were: fadE-L2 5'-CGGGCAGGTGCTATGACCAGGAC (SEQ ID NO: 11); and fadE-R1 5'-CGCGGCGTTGACCGGCAGCCTGG (SEQ ID NO: 12)

[00120] After the fadE deletion was confirmed, a single colony was used to remove the KmR marker using the pCP20 plasmid as described by Datsenko et al., supra. The resulting E. coli MG1655 strain with the fadE gene deleted and the KmR marker removed was named E. coli MG1655 ΔfadE, or E. coli MG 1655 D1. The production of fatty acid derivatives (total fatty species) by E. coli strain MG1655 with the fadE gene was compared with the production of fatty acid derivatives by E. coli MG1655. The fadE gene deletion did not affect the production of fatty acid derivatives (Figure 7). Several exemplary host cell strains are described herein, examples of which are described below in Table 3. Table 3: Genetic Characterization of E. coli Strains

[00121] Plasmids pDG109, pLC56 and pV171.1 are pCL_Ptrc_carB_tesA_alrA_fabB_fadR operons with variable expressions of carB and tesA. iFAB138 is SEQ ID NO: 19.

EXAMPLE 2 Increased Flow Through the Fatty Acid Synthesizer Path - Acetyl-CoA Mediated by Carboxylase Fatty Ester Production:

[00122] The main precursors for fatty acid biosynthesis are malonyl-CoA and acetyl-CoA (Figure 1). It has been suggested that these precursors limit the rate of fatty acid biosynthesis in E. coli. In this example, the accsynthetic operons [accABCD (±birA) from Corynebacterium glutamicum] were overexpressed and the genetic modifications led to increased production of acetyl-CoA and malonyl-CoA in E. coli. In one approach, in order to increase malonyl-CoA levels, an acetyl-CoA carboxylase enzyme complex from Corynebacterium glutamicum (C. glutamicum) was overexpressed in E. coli. Acetyl-CoA carboxylase (acc) consists of four discrete subunits, accA, accB, accC and accD (Figure 3). The advantages of C. glutamicum acc are that two subunits are expressed as fusion proteins, accCB and accDA, respectively, which facilitates their balanced expression. Additionally, C. glutamicum birA, which biotinylates the accB subunit (Figure 3) was overexpressed. Exemplary C. glutamicum birA DNA sequences are shown as SEQ ID NO: 55 and SEQ ID NO: 56. A C. glutamicum birA protein sequence is shown as SEQ ID NO: 57.

[00123] The synthetic operons of the acc genes of C. glutamicum were cloned as follows into OP80 (see WO2008/119082 as incorporated by reference herein) Ptrc1-accDACB, Ptrc3-accDACB, Ptrc1-accCBDA and Ptrc3-CBDA . Ptrc1 and Ptrc3 are derived from the commonly used Ptrc promoter, which allows for attenuated transcription of target genes. It should be noted that the native sequences were amplified from chromosomal DNA as they showed favorable codon usage (only the codon for Arg6 in accCB was altered). The birA gene from C. glutamicum was an improved codon obtained by genetic synthesis. It was cloned downstream of the acc genes in all four operon constructs. Below, reference is made to the accDACB operon configuration as accD- and the accDACB+birA operon configuration as accD+. The resulting plasmids were transformed into E. coli DAM1_i377, which contain integrated copies (i) of thiosterase 'tesA without leader sequence and fadD of E. coli acyl-CoA synthetase and Marinobacter hydrocarbonoclasticus ester synthase 9 (ES9) (SEQ ID NO: 6). All genes are controlled by Ptrc promoters. Strains were grown in 5NBT medium (described below) in shake flasks and analyzed for malonyl-CoA using the short chain CoA assay described below. Figure 8 shows that six of the eight acc±birA structures from C. glutamicum showed high levels of malonyl-CoA in logarithmic phase, which demonstrates its functionality in E. coli. BirA co-expression was found to further increase malonyl-CoA levels in Ptrc1/3_accDACB strains, in particular with the plasmid containing the Ptrc3-accDACB-birA operon configuration (plasmid pASl19.50D; SEQ ID NO: 62) .

[00124] In order to test the effect of combining panK overexpression with acc-birA, the improved panK gene was cloned downstream of birA into Ptrc1/3_accDACB-birA. The panK (or CoaA) pantothenate kinase catalyzes the first step in the biosynthesis of coenzyme A, an essential cofactor that is involved in many reactions, for example, in the formation of acetyl-CoA, the substrate for acetyl-CoA carboxylase. The resulting plasmids were transformed into DAM1_i377, grown in 5NBT medium (+TVS1) in shake flasks and the strains analyzed for short chain CoAs using the method described below. As shown in Figure 9, in the log phase, panK co-expression additionally increased malonyl-CoA levels and also increased acetyl-CoA levels, demonstrating that panK can further increase malonyl-CoA levels. The impact of co-expressing an acetyl-CoA carboxylase enzyme complex on fatty ester production was evaluated by expressing ester synthase 9 (SEQ ID NO: 6) with and without acc genes in another E. coli producing host. More specifically, plasmids OP80 (control vector), pDS57 (with ES9), pDS57-accD- (with ES9 and accDACB) or pDS57-accD+ (with ES9 and accDACB-birA; SEQ ID NO: 63) were transformed into the strain E. coli DV2 and corresponding transformants were selected on LB plates supplemented with 100 mg/l spectinomycin.

[00125] Two transformants from each plasmid were independently inoculated into LB medium supplemented with 100 mg/L spectinomycin and grown for 5 to 8 hours at 32°C. The cultures were diluted 30 times in a minimal medium with the following composition: 0.5 g/l of NaCl, 1 mM of MgSO4 x 7 of H2O, 0.1 mM of CaCl2, 2 g/l of NH4Cl, 3 g /l KH2PO4, 6 g/l Na2HPO4, 1 mg/l thiamine, 1x trace metal solution, 10 mg/l iron citrate, 100 mM Bis-Tris (pH7.0), 30 g/l l of glucose and 100 mg/l of spectinomycin. After overnight growth at 32 °C, cultures were diluted 10-fold in quadruplicate in minimal medium of the same composition, except that the medium contained 1 g/l instead of 2 g/l NH4Cl and was supplemented with 1 mm of IPTG and 2% (v/v) methanol. The resulting cultures were then grown at 32°C on a shaker. The production of fatty acid methyl esters (FAMEs) was analyzed by gas chromatography with a flame ionization detector (GC-FID). Samples were extracted with butyl acetate at a ratio of 1:1 vol/vol. After swirling, the samples were centrifuged and the organic phase was analyzed by gas chromatography (GC). Analysis conditions were as follows: instrument: Trace GC Ultra, Thermo Electron Corporation with a Flame Ionization Detector (FID); column: DB-1 (1% diphenyl siloxane; 99% dimethyl siloxane) CO1 UFM 1/0.1/5 01 DET from Thermo Electron Corporation, pH 5 phase, FT: 0.4 μm, length 5 m, diameter internal: 0.1 mm; inlet conditions: method without separation at 250 °C, with separation at 3.8 m 1/25 used depending on sample concentration with separate flow of 75 ml/m; carrier gas and its flow rate: Helium, 3.0 ml/m; block temperature: 330°C; oven temperature: 0.5m held at 50°C, 100°C/m at 330°C, 0.5m held at 330°C; detector temperature: 300°C; injection volume: 2 μl; run time/flow rate: 6.3 m/3.0 ml/m (no separation method), 3.8 m/1.5 ml/m (1/25 separation method), 3.04 m /1.2 ml/m (method with 1/50 separation). The FAMEs produced are shown in Figure 10. Expression of ES9 alone in E. coli DV2 led to production of FAME above the control DV2 OP80. Co-expression of the C. glutamicum acetyl-CoA carboxylase complex led to a 1.5-fold increase in FAMEs and additional expression of the C. glutamicum biotin protein ligase led to an approximate 5-fold increase in FAMEs. These results suggest that increased provision of malonyl-CoA improves the ability of ES9 to convert fatty acid biosynthetic machinery intermediates to fatty acid methyl esters in E. coli.

Solução de Vitaminas Residuais concentradas 1.000 vezes 0,06 g/l de Riboflavina 6 g/l de Niacina 5,4 g/l de Ácido Pantotênico 1,4 g/l de Piridoxina 0,06 g/l de Biotina 0,01 g/l de Ácido Fólico Solução de Metais Residuais concentrados 1.000 vezes 2 ml/l de Ácido clorídrico concentrado 0,5 g/l de Ácido Bórico 1,9 g/l de Sulfato de cobre, pentaidrato, USP 1 g/l de cloreto de zinco anidro 2 g/l de desidrato de molibdenato de sódio 3 g/l de desidrato cloreto de cálcio[00126] Short Chain CoA Assay: 15 ml falcon tubes were prepared with 0.467 ml of 10% TCA with crotonyl-CoA as the internal standard and overlaid with 2 ml of silicone oil. The tubes were generally cooled and a fermentation broth equivalent to 1 ml of OD600 = 31.2 was carefully placed on top of the silicone oil. Samples were centrifuged at 11,400 G at 4 °C for four 4-minute cycles. For each sample, a 400 ml aliquot of TCA/cell extract was removed and placed in a fresh Eppendorf tube for neutralization with 1 ml of Octylamine (in CHCl3). After swirling, the samples were centrifuged for 30 seconds at 13,000 G. 200 ml of the top layer was filtered using a 0.2 µm PTFE syringe filter and then subjected to LC-MS/MS analysis. Description of the medium used in the experiments

Concentrated Residual Vitamin Solution 1,000 times 0.06 g/l of Riboflavin 6 g/l of Niacin 5.4 g/l of Pantothenic Acid 1.4 g/l of Pyridoxine 0.06 g/l of Biotin 0.01 g /l of Folic Acid Residual Metals Solution concentrated 1,000 times 2 ml/l of concentrated hydrochloric acid 0.5 g/l of Boric Acid 1.9 g/l of Copper Sulfate, pentahydrate, USP 1 g/l of chloride anhydrous zinc 2 g/l sodium molybdenate dehydrate 3 g/l calcium chloride dehydrate

Fatty Alcohol Production:

[00127] The impact of co-expression of the acetyl-CoA carboxylase enzyme complex on fatty alcohol production was evaluated by expressing Acyl-ACP reductase (AAR) from Synechococcus elongatus (SEQ ID NO: 38) with and without acc genes in E. coli DV2. The accD+ operon configuration was selected as it gave the best result when co-expressed with ester synthase (see previous example). The accDABC-birA operon was cloned downstream of the aar gene into pLS9-185 (a derivative of pCL1920) using Infusion technology (Clontech Laboratories, Inc., Mountain View, CA). The resulting plasmid was transformed into E. coli DV2 and corresponding transformants were selected on LB plates supplemented with 100 mg/l spectromycin. The fatty alcohols produced are shown in Figure 11. Co-expression of AAR and accD+ led to a 1.5-fold increase in ca. in fatty alcohol titrations compared to the AAR-only control (pLS9-185). Data were reproducible (triplicate samples were shown). These results demonstrated that increasing malonyl-CoA levels led to improved fatty acid production when this acyl-ACP reductase is used. Additionally, Example 3 describes the co-expression of acc genes along with full-length fab operons.

EXAMPLE 3 Increased Flow Through the Fatty Acid Synthesizing Trajectory - iFABs Production of Fatty Acid Derivatives

[00128] Strategies to increase the flux through the synthetic fatty acid pathway in recombinant host cells include both the overexpression of native E. coli fatty acid biosynthesis genes and the expression of exogenous fatty acid biosynthesis genes from different organisms in E. coli. In this study, fatty acid biosynthetic genes from different organisms were combined with the E. coli DV2 genome (Table 3) under the control of the lacUV5 promoter and integrated into the IS5-11 site. Sixteen strains containing iFABs 130 to 145 were evaluated. The detailed structure of iFABs 130 to 145 is presented in Tables 4 and 5. Table 4: Components of different species used in iFABs 130 to 145

[00129] Each "iFAB" included several fab genes in the following order: 1) An enoyl-ACP reductase (BS_fabI, BS_FabL, Vc_FabV or Ec_FabI); 2) A b-ketoacyl-ACP synthetase III (St_fabH); 3) A malonyl-CoA-ACP transacylase (St_fabD); 4) A b-ketoacyl-ACP reductase (St_fabG); 5) Uma3-hydroxy-acyl-ACP dehydratase (St_fabA or St_fabZ); 6) A b-ketoacyl-ACP synthetase II (Cac_fabF). It should be verified that St_fabA also has trans-2, cis-3-decenoyl-ACP isomerase activity and that Cac_fabF has b-ketoacyl-ACP synthetase II and b-ketoacyl-ACP synthetase I activities (Zhu et al., BMC Microbiology 9: page 119 (2009)). See Table 5, below, for the specific composition of iFABs 130 to 145. Table 5: Composition of iFABs 130

[00130] The pCL_Ptrc_tesA plasmid was transformed into each of the strains and a fermentation was performed in FA2 medium 20 hours after induction to perform a harvest at either 32 °C or 37 °C. Data for the production of total fatty species from duplicate plate screens are shown in Figures 12A and 12B. From this screening, it was determined that the best construct was DV2 with iFAB138. The iFAB138 sequence in the EG149 genome is shown as SEQ ID NO: 19.

Fatty Ester Production:

pDS57 = pCL_ptrc- ES9[00131] A fully synthetic fab operon was integrated into E. coli chromosome and evaluated for increased production of FAME by expression in E. coli DAM1 pDS57. Additionally, four accynthetic operons from Corynebaterium glutamicum were co-expressed and evaluated for improved productivity of FAME. Several strains that produced FAMEs at a faster rate and at higher titers were obtained. The sixteen different iFAB operons (Table 5) were placed under the control of the lacUV5 promoter and integrated into the IS5-11 site of E. coli DAM1. These strains were named DAM1 ifab130 to igabl145. They were transformed either with pDS57 (which contains ester synthase 377) or with pDS57 which co-expresses different versions of acc operons (see above) for the evaluation of FAME production. Exemplary plasmids are described in Table 6. Table 6: Plasmids containing ES9 Synthase ester (from Marinobacter hydrocarbonclasticus) and accsynthetic operons (from Corynebactrium glutamicum)

pDS57 = pCL_ptrc-ES9

[00132] DAM1 ifab strains were analyzed in 96-well plates (4NBT medium), shake flasks (5NBT medium) (see above for medium description) and in fermenters at 32°C. The best results were obtained in 96-well plates and in shake flasks, where several DAM1 ifabs with pDS57-acc-birA plasmids showed higher FAME titers. In particular, ifab131, ifab135, ifab137, ifab138 and ifab143 from DAM1 with pDS57-accDACB-birA showed improved titers of 20 to 40%, indicating that greater flux through fatty acid pathways was achieved in these strains, which resulted in a better product formation rate (these results were reproducible in several independent experiments).

Effect of FabH and FabI Overexpression on Fatty Acid Methyl Ester (FAME) Production

Bs: Bacillus subtilis; Ec: Escherichia coli; ADP1 Acinetobacter sp. ADP1; VT8: Marinobacter aquaeolei VT8; Ro: Rhodococcus opacus B4[00133] Strategies to increase flux through the synthetic fatty acid pathway in recombinant host cells include both the overexpression of native fatty acid biosynthesis genes and the expression of heterologous fatty acid biosynthesis genes. FabH and fabI are two fatty acid biosynthetic enzymes that have been shown to be inhibited by feedback (Heath and Rock, JBC 271: pages 1833 to 1836 (1996)). A study was conducted to determine whether FabH and FabI may be rate limiting for FAME production. The fabH and fabI homologues (from E. coli, B. subtilis, ADP1 from Acinetobacter baylyi, VT8 from Marinobacter aquaeoli and Rhodococcus opacus) were overexpressed as a synthetic operon and evaluated in DAM1 pDS57 from E. coli (a strain that observed to be a good FAME producer). In one approach, the fabH and fabI operons were constructed from organisms that accumulate wax (A. baylyi, M. aquaeoli) or triacylglycerides (R. opacus) and integrated into the E. coli DAM1 pDS57 chromosome. In a related approach, accsynthetic operons from C. glutamicum were co-expressed (as described in Example 2, above). Eleven different fabHI operons were constructed (arranged in vitro) as summarized in Table 7. The fabHI operons were placed over the IPTG-inducible lacUV5 promoter control and integrated into the IS5-11 site of E. coli DAM1. These strains were named as shown in the Table below. They were transformed either with pDS57 (which contains ester synthase 377) or with pDS57 that co-expresses different versions of acc operons for the evaluation of FAME production. Table 7: Genotype of Integrated fabHI Operons

Bs: Bacillus subtilis; Ec: Escherichia coli; ADP1 Acinetobacter sp. ADP1; VT8: Marinobacter aquaeolei VT8; Ro: Rhodococcus opacus B4

[00134] ifabHI DAM1 strains were analyzed in 96-well plates (in 4NBT medium), shake flasks (in 5NBT medium) and in fermenters at 32 °C. In a shake flask, several ifabHI strains carrying the pDS57 plasmid performed better than the control DAM1 pDS57 strain, achieving 10 to 15% higher FAME titers (Figure 13). A further increase in FAME titers was obtained when ifabHI strains were transformed with pDS57-acc-birA plasmids, in particular a 50% increase in FAME titers was observed in the StEP156 strain (DAM1 IS5-11::1acUV5(ecRBS)ADPlfabH (ecRBS)ADP1fabI pDS57-accDACB-birA) (Figure 14).

[00135] Some of the strains with ifabHI were run in fermenters, where an increase in FAME titers, specifically productivity and yield, were also observed (Figure 15), which indicates that in these strains, a higher flow through of fatty acid trajectory, which resulted in a better product formation rate. In particular, stEP129 (DAM15-11::UV5(ecRBS)ADPlfabH(ecRBS)ADP1fabI pDS57) showed higher FAME titers and yield in several independent fermentation runs. Other combinations of fabH and fabI can be used to achieve similar effects. Although FAME is exemplified here, this approach to altering fatty acid biosynthetic genes is a useful approach to increasing the production of any fatty acid derivative.

Effect of Inserting a Strong Promoter Ahead of the FAB 138 Operon on Fatty Acid Methyl Ester (FAME) Production:

[00136] The lacUV5 promoter of iFAB 138 was replaced by a T5 promoter (SEQ ID NO: 2) which led to higher levels of expression of iFAB 138, as confirmed by mRNA analysis. The expression of iFAB138 from the T5 promoter resulted in higher titration, yield and productivity of fatty esters. The shu.002 strain (Table 3) is isogenic to the BD64 strain (Table 3), except that it contains the T5 promoter controlling the expression of the iFAB138 operon (SEQ ID NO: 19). Table 8: Initiators Used to Generate Cassette iT5 138 and Verify Their Insertion into New Strains

[00137] The primers DG405 and DG406 (Table 8) were used to amplify a cat-loxP and T5 promoter cassette with the addition of 50 bp of homology to each end of the PCR product, so that they could be integrated into any strain by replacing the regulatory expression of the lacUV5 promoter of the iFAB138 operon. The cat-loxP-T5 promoter was transformed into the BD64/pKD46 strain. The transformants were recovered on LB + chloramphenicol plates at 37 °C overnight, added to a new LB + chloramphenicol plate and verified by colony PCR using primers DG422 and DG423. Plasmid pJW168 (Palmeros et al, Gene 247: pages 255 to 264 (2000)) was transformed into strain BD64 i-cat-loxP-T5_138 and selected on LB + carbenicillin plates at 32°C. In order to remove the cat tag, cre-recombinase expression was induced by IPTG. Plasmid pJW168 was removed by growing cultures at 42°C. Colonies were pooled in LB + chloramphenicol and LB + carbenicillin to verify pJW168 loss and cat marker removal, respectively. The colony was also pooled in LB as a positive control, all pooled plates were incubated at 32°C. Removal of the cat marker was confirmed by colony PCR using primers DG422 and DG423. The resulting PCR product was verified by sequencing with primers EG744, EG749 and oTREE047, the strain was named shu.002. Figure 16 shows the iFAB138 locus: a diagram of the cat-loxP-PT5 cassette integrated in front of the FAB 138 (Figure 16A) and a diagram of the PT5_IFAB138 region (Figure 16B). The cat-loxP-T5 promoter sequence integrated in front of iFAB138 with homology to the integration site is shown as SEQ ID NO: 1 and the sequence of the iT5_FAB138 promoter region with homology to the integration site is shown as SEQ ID NO: 2 There are several conditions that can lead to increased flow of fatty acid. In this example, increased fatty acid flux was achieved by changing the promoter strength of the iFAB138 operon. The expression of iFAB138 from the T5 promoter was beneficial, in any case, when this promoter change was combined with the insertion of the yijP::Tn5 cassette, further improvements were observed in titration, yield and productivity of fatty acid esters and other fatty acid derivatives (data not shown).

EXAMPLE 4 Increased Amount of Free Fatty Acid Product (FFA) by Repairing rpg and iLvG Mutations

[00138] The ilvG and rph mutations were corrected in this strain, which resulted in increased production of FFA. Strains EG149 and V668 (Table 3) were transformed with pCL_Ptrc_tesA. Fermentation was performed at 32 °C in FA2 medium for 40 hours to compare the FFA production of strains EG149 and V668 with pCL_Ptrc_tesA. Correcting the rph and ilvG mutations resulted in a 116% increase in FFA production from the base strain with pCL_Ptrc_tesA. As seen in Figure 17, V668/pCL_Ptrc_tesA produced more FFA than the control EG149/pCL_Ptrc_tesA. Given that FFA is a precursor to LS9 products, higher production of FFA is a good indicator that the new strain can produce higher levels of LS9 products.

EXAMPLE 5: Increased Production of Fatty Acid Derivatives by Transposon yijP Mutagenesis Fatty Alcohol Production:

[00139] To improve the titration, yield and productivity of fatty alcohol production by E. coli, transposon mutagenesis and high-throughput screening were performed and beneficial mutations were sequenced. An insertion of transposon into the strain has been shown to improve the strain's fatty alcohol yield in both shake flask and fed-batch fermentations. The SL313 strain produces fatty alcohols. The genotype of this strain is given in Table 3. The transposon clones were then subjected to high-flow screening to measure the production of fatty alcohols. Briefly, colonies were fished into deep well plates containing LB, grown overnight, inoculated into fresh LB and grown for 3 hours, inoculated into fresh FA2.1 medium, grown for 16 hours and then extracted using acetate. butyl. The crude extract was derived with BSTFA (N,0-bis[Trimethylsilyl]trifluoroacetamide) and analyzed using GC/FID. Spectomycin (100mg/l) was included in all media to maintain plasmid pDG109 selection. Placements were selected by choosing clones that produced total fatty species similar to the control strain SL313, but had a higher percentage of fatty alcohol species and a lower percentage of free fatty acids than the control. Strain 68F11 was identified as a placement and was validated in a shake flask fermentation using FA2.1 medium. A comparison of transposon placement 68F11 with the control strain SL313 indicated that 68F11 produces a higher percentage of fatty alcohol species than the control, despite both strains producing similar titers of total fatty species. A single colony of placement 68F11, called LC535, was sequenced to identify the location of the transposon insert. Briefly, genomic DNA was purified from a 10 ml overnight LB culture using the ZR Fungal/Bacterial DNA MiniPrep™ Kit (Zymo Research Corporation, Irvine, CA) according to the manufacturer's instructions. Purified genomic DNA was sequenced outwards from the transposon using transposon-internal primers: DG150 5'-GCAGTTATTGGTGCCCTTAAACGCCTGGTTGCTACGCCTG-3'(SEQ ID NO: 27) DG131 5'-GAGCCAATATGCGAGAACACCCGAGAA-3' (SEQ ID NO: 28)

[00140] Strain LC535 was determined to have a transposon insertion in the yijP gene (Figure 18), with yijP encoding a conserved inner membrane protein whose function is unknown. The yijP gene is in an operon and co-transcribed with the ppc gene, which encodes phosphoenolpyruvate carboxylase, and the yijO gene, which encodes a predicted transcriptional regulator of DNA binding of unknown function. Transposon-internal promoters likely have effects on the transcriptional level and timing of yijP, ppc, and yijO and may also have effects on adjacent genes frwD, pflC, pfld, and argE. Promoters internal to the transposon cassette are shown in Figure 18 and may have effects on adjacent gene expression. Strain LC535 was evaluated in a batch fermentation fed on two different dates. Both fermentations demonstrated that LC535 produced fatty alcohols with a higher yield than the control SL313 and that 1.3 to 1.9% improvement in absolute yield based on carbon input. The yijP transposon cassette was further evaluated on a different V940 strain, which produced fatty alcohol in a higher yield than the SL313 strain. The yijP::Tn5-cat cassette was amplified from strain LC535 using the primers: LC277 5'-CGCTGAACGTATTGCAGGCCGAGTTGCTGCACCGCTCCCGCCAGGCAG- 3' (SEQ ID NO: 29) LC278 5'- GGAATTGCCACGGQCGGCAGGCTCCATACGCGAGGCCAGGTTATCCAACG-3' (SEQ ID NO: 29) )

[00141] This linear DNA was electroporated into the SL571 strain and integrated into the chromosome using the lambda red recombination system. Colonies were sorted using primers outside the transposon region: DG407 5'-AATCACCAGCACTAAAGTGCGCGGTTCGTTACCCG-3' (SEQ ID NO: 31) DG408 5'-ATCTGCCGTGGATTGCAGAGTCTATTCAGCTACG-3' (SEQ ID NO: 32)

[00142] A colony with the correct yijP transposon cassette was transformed with the production plasmid pV171.1 to produce the D851 strain. D851 was tested in a shake flask fermentation against strain V940 that did not contain the yijP transposon cassette. The result of this fermentation showed that the transposon cassette yijP confers the production of a higher percentage of fatty alcohol by the strain D851 in relation to the strain V940 and produces similar titers of total fatty species to the control strain V940. Strain D851 was evaluated in a batch fermentation fed on two different dates. Data from these fermentations are shown in Table 9 which illustrates that in the 5 liter fed-batch fermentations, strains with the transposon insertion yijP::Tn5-cat had an increase in total fatty species ("FAS") yield and a increase in the percentage of fatty alcohol ("FALC"). The terms "total fatty species" and "total fatty acid product" may be used interchangeably herein to refer to the amount of free fatty alcohols, fatty aldehydes and fatty acids as evaluated by GC-FID as described in the Application for International Patent WO 2008/119082. The same terms can be used to mean fatty esters and free fatty acids when referring to a fatty ester analysis. As used herein, the term "fatty esters" includes beta hydroxy esters. Table 9: Effect of yijP transposon insertion on titration and yield of FAS and FALC

Fermentation Tank Method:

[00143] To determine the production of fatty acid and fatty acid derivatives in a tank, a vial of glycerol of the desired strain was used to inoculate 20 ml of LB + spectromycin in a shake flask and incubated at 32 °C for approximately six hours. 4 ml of the LB culture was used to inoculate 125 ml of Low PFA Inoculum (below), which was then incubated at 32°C on a shaker overnight. 50 ml of the overnight culture was used to inoculate 1 liter of Tank Medium. The tanks were run at pH 7.2 and 30.5 °C under static pH conditions with a maximum glucose feed rate of 16 g/l/h. Table 10: Low PFA Inoculum:

[00144] Additional studies suggest that the improved titration and yield of FAS and FALC in strains with the yijP transposon insertion is due to the reduction in phosphoenolpyruvate carboxylase (ppc) activity. A ppc enzyme assay was performed in vitro on the following strains to evaluate this hypothesis. 1) Δppc = DG14 (LC942 Δppc::cat-sacB/pLC56) 2) wt-ppc = DG16 (LC942/pLC56) 3) yijP::Tn5 = DG18 (LC942 yijP::Tn5-cat/pLC56)

[00145] Ppc activity was measured in cells grown in a shake flask fermentation using a standard shake flask protocol in FA2.3 medium (described above) and harvested 12 to 16 hours after induction. Approximately 5 ml of cells were centrifuged and the cell paste was suspended in the BugBuster Protein Extraction Reagent (Novagen) with a protease inhibitor cocktail solution. The cell suspension was incubated with gentle shaking on a shaker for 20 minutes. Insoluble cell debris was removed by centrifugation at 16,000G for 20 minutes at 4°C and then the supernatant was transferred to a new tube. The ppc activity in the cell lysate was determined by a citrate synthase coupling reaction using the following reaction mixture: 0.4 mM acetyl-CoA, 10 mM phosphoenolpyruvate, 0.5 mM monobromobimane, 5 mM MgCl2, 10 mM NaHCO3 and 10 units of porcine heart citrate synthase in 100 mM Tris-HCl (pH 8.0). CoA formation in the reaction with citrate synthase using oxaloacetate and acetyl-CoA was monitored photometrically using fluorescent shunt of CoA with monobromobimane. The results of the Ppc assay showed that the yijP::Tn5-cat transposon cassette decreased Ppc activity in the cell by 2.7-fold compared to wild-type cells. The ppc-deleted cells did not develop well and the activity was approximately 10-fold lower than wild-type cells. The results also indicated that the highest yield of fatty alcohol production requires a lower Ppc expression level than the wild-type level. Proteomic data were collected to determine the abundance of Ppc protein in the two strains with and without the yijP::Tn5-cat transposon cassette. Protein samples were collected from strains V940 and D851 grown in bioreactors under standard fatty alcohol production conditions (described above). Samples were taken at two different times: 32 and 48 hours and prepared for analysis.

[00146] Sample collection and protein isolation were performed as follows:

[00147] 20 ml of fermentation broth were collected from each bioreactor at each time point. Samples were quenched with PBS at freezing temperatures and collected by centrifugation (4,500 rpm/10 minutes) at 4°C. Cell pellets were washed with PBS at ice-cold temperatures, centrifuged once more and stored at -80°C for further processing.

[00148] Total protein extraction was carried out using a French press protocol. Briefly, the cell pellets were resuspended in 7 ml of PBS at ice-cold temperatures and French pressed at 2000 psi twice to ensure complete lysis of the bacteria. Samples were centrifuged for 20 minutes at 10,000 rpm at 4 °C to separate unlysed cells and cellular debris from the protein fraction. The total protein concentration of clear lysate was determined using BCA Protein Assay Reagent. Samples were diluted to a concentration of 2 mg protein/ml and frozen at -80°C.

[00149] Samples were resuspended in the appropriate buffer and trypsinized overnight at 37°C and lyophilized. The fragmented protein samples were identified with isotopically enriched methylpiperazine acetic acid at room temperature for 30 minutes. The identified samples were separated using cation exchange liquid chromatography and subjected to mass spectrometry analysis using an ion trap mass spectrometer. Raw data were normalized using background subtraction and bias correction.

[00150] The proteomic data showed a significant reduction in the relative abundance of Ppc protein in strain D851 when compared to V940 at 32 hours and 48 hours. D851 had approximately 15% of V940's Ppc levels at 32 hours and approximately 35% of V940's Ppc levels at 48 hours. These data showed that the yijP::Tn5-cat transposon cassette resulted in a significant reduction in the abundance of Ppc in the cell. This suggests that the observed benefits to the production of fatty alcohol by strains that carry the yijP::Tn5-cat transposon placement is due to the reduction in the amount of the Ppc protein.

[00151] These results suggest that altering the ppc activity can improve the yield of fatty acid derivatives. There are several ways to change the expression of the ppc gene and the insertion of the yijP transposon is one way to achieve this. Without wishing to be bound by theory, if the effect of reducing phosphoenolpyruvate carboxylase activity is to limit the flow of carbon through the TCA cycle, one could achieve similar results by decreasing citrate synthase (gltA) activity or slowing it down. if the TCA cycle is reduced by decreasing the activity of any of the enzymes involved in the TCA cycle.

EXAMPLE 6 Increased Flux Through Fatty Alcohol Production Mediated by Fatty Acid Synthesizing Trajectory and Acyl Carrier Protein (ACP)

[00152] When terminal pathway enzymes from sources other than E. coli expressed in E. coli as the heterologous host to convert Fatty Acyl-ACPs into products, limitations may exist in recognition, affinity and/or diversion of the recombinant pathway enzyme in favor of E. coli fat acyl-ACPs. It should be noted that although ACP proteins are conserved to some extent in all organisms, their primary sequence can differ significantly. To test this hypothesis, the ACP genes of several cyanobacteria were cloned downstream from the Synechococcus elongatus PCC7942 acyl-ACP reductase (AAR) present in pLS9-185, which is a derivative of pCL1920. Additionally, the sfp gene (Accession No. X63158; SEQ ID NO: 53) from Bacillus subtilis, which encodes a phosphopantetheinyl transferase with broad substrate specificity, was cloned downstream of the respective acp genes. This enzyme is involved in the conversion of inactive apo-ACP to active holo-ACP. The plasmids constructed are described in Table 12. Table 12: Cyanobacteria ACP co-expressing plasmids with and without B. subtilis sfp downstream of the S. elongates PCC7942 AAR

[00153] All ACP genes were cloned with a synthetic RBS at the EcoRI site immediately downstream of the aar gene in pLS9-185 using InFusion technology (Clontech Laboratories, Inc., Mountain View, CA). The EcoRI site was reconstructed downstream of the ACP gene. Similarly, the B. subtilis sfp gene was cloned by InFusion into the EcoRI site along with a synthetic RBS. All plasmids were transformed into E. coli MG1655 DV2 (Table 3). The control for these experiments was AAR expression alone (pLS9-185). The results of standard shake flask fermentation experiments are shown in Figure 19. A significant improvement in fatty alcohol titrations was observed in strains containing the plasmids pDS171S, pDS172S, pDS168 and pDS169, which demonstrates that overexpression of ACP can be beneficial for the production of fatty alcohol, in this case presumably due to the aid in the recognition, affinity and/or diversion of acyl-ACPs by the terminal-path heterologous enzyme. (See Table 12 for source of ACPs and presence or absence of sfp).

Fatty Acid Production:

[00154] In order to assess whether the overexpression of an ACP can also increase the production of free fatty acids, a cyanobacterial ACP gene with sfp was amplified from pDS171s (Table 12) and cloned downstream from 'tesA in a pCL vector. The resulting operon was under the control of the trc3 promoter, which provides marginally lower levels of transcription compared to the wild-type trc promoter. The construct was cloned into E. coli DV2 and evaluated for fatty acid production. The control strain contained the identical plasmids, but without the cyanobacterial ACP and the B. subtilis sfp. The results of a standard microtiter plate fermentation experiment are shown in Figure 20. A significant improvement in fatty acid titration was observed in the strain co-expressing heterologous ACP, which demonstrates that overexpression of ACP can be beneficial for the production of fatty acid, in this case presumably due to increased flux through the fatty acid biosynthetic pathway.

Claims (14)

1. A recombinant E. coli host cell characterized in that it comprises a transposon insertion into an E. coli cell yijP gene, wherein the yijP gene is flanked by the E. coli ppc gene, and wherein the transposon insertion regulates descending the ppc gene, wherein said recombinant E. coli host cell produces a fatty acid-derived composition at a titer, yield or productivity superior to a corresponding wild-type E. coli cell when cultured in a medium containing a source of carbon under conditions effective to express said ppc gene, wherein said fatty acid derivative composition comprises a fatty acid derivative selected from the group consisting of a fatty acid, a fatty ester, a fatty alcohol, a fatty aldehyde, a alkane, a terminal olefin, an internal olefin and a ketone and wherein said E. coli host cell is strain D851. 2. Cell culture characterized in that it comprises the recombinant E. coli host cell as defined in claim 1. 3. Cell culture, according to claim 2, characterized in that said medium comprises the composition derived from fatty acid. 4. Cell culture, according to claim 3, characterized in that the fatty acid derivative is a) a C6, C8, C10, C12, C13, C14, C15, C16, C17 or C18 fatty acid derivative, or b) a C10:1, C12:1, C14:1, C16:1, or C18:1 unsaturated fatty acid derivative. 5. Cell culture, according to claim 3, characterized in that the fatty acid-derived composition comprises a) one or more of the C8, C10, C12, C14, C16 and C18 fatty acid derivatives, b) fatty acids, c) fatty aldehydes, d) fatty alcohols, e) fatty esters, f) alkanes, g) terminal olefins, h) internal olefins, or i) ketones. 6. Cell culture according to claim 3, characterized in that the fatty acid-derived composition comprises fatty acid derivatives having a double bond at position 7 in the carbon chain between C7 and C8 of the reduced end of the fatty alcohol. 7. Cell culture, according to claim 3, characterized in that the fatty acid-derived composition comprises unsaturated fatty acid derivatives. 8. Cell culture, according to claim 3, characterized in that the fatty acid-derived composition comprises saturated fatty acid derivatives. 9. Cell culture, according to claim 3, characterized in that the fatty acid-derived composition comprises branched-chain fatty acid derivatives. 10. Cell culture according to claim 2, characterized in that said recombinant E. coli host cell has a titer that is 5% higher than a titer of said corresponding wild-type E. coli host cell when grown under the same conditions as the recombinant E. coli host cell. 11. Cell culture, according to claim 10, characterized in that said recombinant E. coli host cell has a titer of 1g/L to 250 g/L. 12. Cell culture, according to claim 11, characterized in that said recombinant E. coli host cell has a titer of 90 g/L to 120 g/L. 13. Cell culture, according to claim 2, characterized in that said recombinant E. coli host cell has a yield that is from 10% to 40%, preferably a yield of 25%. 14. Cell culture, according to claim 2, characterized in that said productivity is in the range of 0.7 mg/L/h to 3g/L/h.

Images